Detection of sepsis using hematological parameters
By calculating the NLR, WBC and monocyte population parameters in blood samples and combining with threshold comparison, the problem of insufficient specificity of sepsis screening tools in the emergency department is solved, and the efficient early stage of sepsis and septic shock is achieved Identification improves diagnostic performance.
Patent Information
- Application Number
- CN202380022101.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-18
- Filing Date
- 2023-02-17
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art sepsis screening tools are limited in emergency departments, the clinical scoring system with routine available information lacks specificity, and biomarkers such as lactic acid, CRP and procalcitonin are insufficient for early identification of sepsis. And the application is limited in ED environment.
By calculating neutrophil-lymphocyte ratio (NLR), white blood cell count (WBC), and monocyte population parameters in blood samples, combined with threshold comparison, identifying the risk of sepsis or septic shock in patients, providing early screening and diagnosis.
Achieve high sensitivity and specific screening for sepsis and septic shock. Combined MDW, WBC and NLR improve diagnostic performance, with AUC reaching 0.86, significantly improving sensitivity and specificity, better than that of biologically used alone Marker.
Smart Images

Figure CN119072630A_ABST
Abstract
Description
[0001] Government funding
[0002] This invention was made with government support under Grant HS026640-02 awarded by the U.S. Department of Health and Human Services. The government has certain rights in this invention. Background Art
[0003] Sepsis is a leading cause of morbidity and mortality worldwide and is responsible for more than 1.5 million hospitalizations and 250,000 deaths each year in the United States. Early initiation of targeted therapies for sepsis improves patient outcomes and reduces costs, but reliable identification of sepsis remains challenging. Summary of the invention
[0004] In one aspect, the present disclosure describes a method for screening for sepsis or septic shock in a patient. The method includes: calculating a neutrophil to lymphocyte ratio (NLR) of a blood sample from the patient; characterizing a white blood cell count (WBC) of the blood sample; calculating a monocyte population parameter of the blood sample; comparing the NLR to a first predetermined threshold set, comparing the WBC to a second predetermined threshold set, and comparing the monocyte population parameter to a third predetermined threshold set; and identifying patients on a low to high risk spectrum for sepsis or septic shock. In some embodiments, the method includes reporting the patient's identified risk to a clinician in a view within an electronic medical record (EMR).
[0005] The words "preferred" and "preferably" refer to embodiments or aspects of the present invention that may provide certain benefits in certain circumstances. However, other embodiments or aspects may also be preferred under the same or other circumstances. In addition, the recitation of one or more preferred embodiments or aspects does not mean that other embodiments or aspects are not useful, and is not intended to exclude other embodiments or aspects from the scope of the present invention.
[0006] The term "comprises" and its variations do not have a limiting meaning where these terms appear in the specification and claims. Such terms will be understood to imply the inclusion of the stated steps or elements, or groups of steps or elements, but not the exclusion of any other steps or elements, or groups of steps or elements.
[0007] “Consisting of is meant to include and be limited to whatever follows the phrase “consisting of.” Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that other elements may not be present. “Consisting essentially of is meant to include any elements listed after the phrase, and be limited to other elements that do not interfere with or contribute to the activity or action specified for the listed elements in the disclosure. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present, depending on whether or not they materially affect the activity or action of the listed elements.
[0008] Unless otherwise specified, "a," "an," "the," and "at least one" are used interchangeably and mean one or more than one.
[0009] As used herein, the term "or" is generally used in its ordinary meaning, including "and / or," unless the content clearly dictates otherwise.
[0010] The term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements.
[0011] Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
[0012] As used herein, "up to" a number (eg, up to 50) includes the number (eg, 50).
[0013] The terms "in the range" or "within a range" (and similar expressions) include the endpoints of the range.
[0014] For any method disclosed herein that comprises discrete steps, the steps may be performed in any practicable order. And where appropriate, any combination of two or more steps may be performed simultaneously.
[0015] Unless otherwise indicated, all headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading.
[0016] References throughout this specification to "one embodiment," "one aspect," "an embodiment," "aspect," "certain embodiments," "certain aspects," "some embodiments," or "some aspects" mean that the specific features, configurations, compositions, or characteristics described in conjunction with the embodiment are included in at least one embodiment of the present disclosure. Therefore, the appearance of such phrases in multiple places throughout this specification does not necessarily refer to the same embodiment of the present disclosure. In addition, specific features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments or aspects.
[0017] Unless otherwise indicated, all numerals used in the specification and claims to represent the amount of components, molecular weight, etc. should be understood to be modified by the term "about" in all cases. As used herein, the term "about" related to a measured amount refers to a variation of the measured amount, as would be expected by a person skilled in the art when making measurements and taking a level of care commensurate with the purpose of the measurement and the accuracy of the measuring equipment used. Therefore, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximate values, which may vary according to the desired properties sought to be obtained by the present invention. At least, and without attempting to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be interpreted according to the numerical value of the reported significant figures and by applying general rounding techniques.
[0018] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain ranges necessarily resulting from the standard deviation found in their respective testing measurements.
[0019] The above summary of the present invention is not intended to describe every disclosed embodiment or every implementation of the present invention. The following description illustrates illustrative aspects in more detail. In several places throughout the application, guidance is provided by lists of examples, which can be used in various combinations. In each case, the enumerated lists serve only as representative groups and should not be interpreted as exclusive lists. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Illustrative embodiments of the present invention are described in detail below with reference to the accompanying drawings, and in which:
[0021] Figure 1 A study flow chart for the study described in Example 1 is shown.
[0022] Figure 2 Comparison of monocyte distribution width, white blood cell count and neutrophil to lymphocyte ratio for each group is shown. Dashed lines indicate the cutoff value for each test.
[0023] Figure 3ALactate for each group compared to leukocyte measurements of the same subset is shown, and Figure 3B C-reactive protein for each group compared to leukocyte measurements of the same subsets is shown. The dashed lines in each panel indicate the cutoff values for the respective test. Sepsis and septic shock were defined according to the Sepsis-3 consensus definition. Abbreviations: CRP: C-reactive protein, MDW: .
[0024] Figure 4 Comparison of monocyte distribution width, white blood cell count, and neutrophil to lymphocyte ratio in each group in the immunosuppressed patient subgroup is shown. The dashed line in each panel indicates the cutoff value for each test. The immunosuppressed patient subgroup was identified by active questions with neutropenia or meeting criteria for an immunocompromised state.
[0025] Figure 5 is a schematic description of an example operating environment in accordance with aspects of the present disclosure.
[0026] Figure 6 is a schematic description of an example analyzer in accordance with aspects of the present disclosure.
[0027] Figure 7 is a schematic description of an example analyzer process in accordance with aspects of the present disclosure.
[0028] Figure 8 is a schematic description of an example analysis engine in accordance with aspects of the present disclosure.
[0029] Fig. 9 Depicted is a flow chart of an example method for assessing sepsis or septic shock from a blood sample in accordance with aspects of the present disclosure.
[0030] Fig.10 Depicted are examples of converting blood sample parameters into an index that identifies patients on a low-risk to high-risk spectrum for sepsis and septic shock in accordance with aspects of the present disclosure.
[0031] Fig.11 Depicted are example procedures and laboratory outputs for visualization by a clinician in accordance with aspects of the present disclosure. DETAILED DESCRIPTION
[0032] The present disclosure describes methods and systems for screening for sepsis or septic shock in a patient using a white blood cell count (WBC), a monocyte population parameter, or a neutrophil to lymphocyte ratio (NLR), or a combination thereof, in a blood sample from the patient, and methods for ruling out sepsis or septic shock in a patient. In some aspects, the method can preferably be used to screen patients in an emergency department (ED).
[0033] Current ED-based sepsis screening tools are limited. Clinical scoring systems that rely on routinely available information have advantages due to their universal applicability. The original systemic inflammatory response syndrome (SIRS) criteria are still widely used for sepsis screening but lack specificity; patients with acute non-infectious illnesses often screen positive. (Sprung et al. Intensive Care Med. 2006; 32(3): 421-427; Bone et al. Chest. 1992; 101(6): 1644-1655). SIRS criteria were excluded from the third-generation consensus sepsis definition (SEP-3), which introduced the quick sequential organ failure assessment score (qSOFA) and has been applied to sepsis screening and prediction. (Singer et al. JAMA. 2016; 315(8): 801-810). Unfortunately, qSOFA has been shown to lack sensitivity in the ED, where patients often present before showing overt signs of organ failure. (Serafim et al. Chest. 2018; 153(3): 646-655). Biomarkers can serve as an aid in sepsis screening and diagnosis. However, currently available biomarkers (including lactate, C-reactive protein, and procalcitonin) may perform suboptimally due to limited diagnostic accuracy, detectable signal delays, and / or lack of widespread availability in clinical settings. (Al Jalbout et al. The Journal of Applied Laboratory Medicine. 2019; 3(4): 724-729; Pierrakos et al. Crit Care. 2020; 24(l): 287).
[0034] While there is increasing work to support sepsis care in the ED using automated algorithms, a single simple biomarker that could enable early identification in an undifferentiated population would be extremely valuable. To date, no such biomarker has been found. Lactate, CRP, and procalcitonin are commonly used for sepsis risk stratification, but none of them show optimal diagnostic performance when used alone. (Lippi, Clinical Chemistry and Laboratory Medicine (CCLM). 2019; 57(9): 1281-1283). Lactate—the only biomarker recommended for use by consensus guidelines—is a nonspecific marker of cellular dysfunction, and increases in lactate do not occur until late in the course of the disease; it is recommended for use in predicting and monitoring response to treatment rather than for case identification. (Rhodes et al. Intensive Care Medicine. 2017; 43(3): 304-377; Casserly et al. Critical Care Medicine. 2015; 43(3)). CRP has been shown to lack sensitivity and specificity for sepsis in an undifferentiated population and is particularly unreliable in the ED setting. (Wasserman et al. Medicine (Baltimore). 2019; 98(2); Wu et al. Ann Intensive Care. 2017; 7). Procalcitonin may play a role in distinguishing bacterial from viral infections, but recent data suggest that its sensitivity for invasive infections is unacceptably low and does not warrant its use as a screening tool. (Goodlet et al. Open Forum Infect Dis. 2020; 7(4); Gregoriano et al. J Thorac Dis. 2020; 12(Suppl 1): S5-S15). The utility of these biomarkers for early sepsis screening is further weakened by availability, which depends on clinical suspicion and is subject to practice variability. For example, lactate, CRP, and procalcitonin are not clinically available in all EDs.
[0035] A complete blood count (CBC) - a test that counts the cells that make up the blood - is the most commonly ordered laboratory panel worldwide (Horton et al. Am J Clin Pathol. 2019; 151(5): 446-451), and is ordered for most patients arriving at the emergency department. Although the CBC has been recognized as a source of a wealth of useful information about patients with sepsis, typical practice is to ignore much of this data and focus only on a single component, the white blood cell count (WBC) (Farkas, J Thorac Dis. 2020; 12(Suppl 1): S16-S21). There is little support for practicing clinicians to use CBC results overall for sepsis testing.
[0036] The WBC was included in the original consensus criteria for sepsis but has been excluded from more recent definitions of sepsis due to its poor diagnostic accuracy when used alone (Bone et al. Chest. 1992; 101(6): 1644-1655). Other components of the CBC—including neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR)—have been considered possible markers of sepsis ( et al. PLoS One. 2017; 12(7): e0181704; Martins et al. Rev Bras Ter Intensiva. 2019; 31(l): 64-70), but are limited in their ability to relate to patient groups with more severe disease. Traditional screening tools (e.g., systemic inflammatory response syndrome (SIRS) criteria, national early warning score (NEWS), modified early warning score (MEWS), rapid sequential organ failure assessment (qSOFA), and sequential organ failure assessment (SOFA) criteria) also show poor diagnostic accuracy. Islam et al. Comput Methods Programs Biomed 2019; 170: 1-9.
[0037] When a CBC is obtained from a blood sample, using an analyzer such as a blood analyzer on the same blood sample can further provide data about cell subpopulations that are much richer than simply counting or proportioning these cells compared to other cell subpopulations within the sample. For example, a monocyte population parameter reflecting monocyte activation can be obtained. One such monocyte parameter is monocyte distribution width (referred to herein as MDW, and also referred to as monocytic anisocytosis). MDW represents the volume distribution of a monocyte population in a blood sample; therefore, this morphological parameter reflects the variability of monocyte volume.
[0038] Due to monocyte activation induced by pathogen recognition, morphological changes in monocyte cell volume occur early, and thus MDW changes early in the disease trajectory. MDW has been shown to be able to identify patients with sepsis in high-risk groups. (Crouser et al. Crit Care Med. 2019; 47(8): 1018-1025; Crouser et al. Chest. 2017; 152(3): 518-526; Crouser et al. Intensive Care. 2020; 8: 33). In addition, MDW and WBC combinations have been proposed for assessing sepsis status. (See, e.g., PCT Application No. PCT / US2019 / 028486).
[0039] The disclosure describes that when MDW is considered together with WBC and NLR, as further described herein (including, for example, in Example 1), surprisingly good predictability is achieved for both sepsis and septic shock. For example, an AUC of 0.86 (Table 2) was achieved for both sepsis and septic shock, and a sensitivity of 92.2% for sepsis, and a sensitivity of 97.7% for septic shock. In addition, the results show that MDW has an important additional effect together with WBC and NLR, and the combination of these three parameters provides a significantly better discrimination of patient outcomes than WBC, NLR or MDW alone or any combination of these parameters. The discovery that the combination of three different parameters (CBC difference) from a single laboratory panel can achieve such a high diagnostic performance is unexpected. For decades, CBC has been used in routine practice, including as a screening laboratory test for infection. However, the use of this CBC parameter combination has never been described, and no previous studies have reported this level of discrimination for sepsis and septic shock using any CBC parameter combination. It is also surprising that the sensitivity achieved using parameter combinations is multiplicative rather than additive.
[0040] Screening Methods for Sepsis or Septic Shock
[0041] In some aspects, the present disclosure describes a method for screening sepsis or septic shock in a patient. The method includes calculating the ratio (NLR) of neutrophils to lymphocytes from a blood sample of the patient; characterizing the white blood cell count (WBC) of the blood sample; and calculating the monocyte population parameter of the blood sample. The method also includes comparing WBC, monocyte population parameters and NLR with a threshold value or a threshold range. For example, NLR can be compared with a first predetermined threshold, WBC can be compared with a predetermined threshold range, and monocyte population parameters can be compared with a second predetermined threshold. At least one of these comparisons is used to determine whether the patient has an increased risk of sepsis or septic shock. In some aspects, the method is an in vitro method.
[0042] In some aspects, screening for sepsis or septic shock comprises diagnosing sepsis or detecting sepsis. However, additionally or alternatively, screening for sepsis or septic shock may comprise predicting the development of sepsis or septic shock within 6 hours, 12 hours, or 24 hours.
[0043] In some aspects, determining whether a patient has an increased risk of sepsis or septic shock includes determining whether at least one of WBC, monocyte population parameters and NLR is greater than a predetermined threshold or outside a predetermined threshold range. For example, the method may include determining that NLR is greater than a first predetermined threshold, WBC is outside a predetermined threshold range, or a monocyte population parameter is greater than a second predetermined threshold, or a combination thereof. In some aspects, determining whether a patient has an increased risk of sepsis or septic shock includes determining that NLR is greater than a first predetermined threshold, and further determining that monocyte population parameters are greater than a predetermined threshold or WBC is outside a predetermined threshold range, or both. In some aspects, determining whether a patient has an increased risk of sepsis or septic shock includes determining that NLR is greater than a first predetermined threshold, and further determining that monocyte population parameters are greater than a predetermined threshold.
[0044] In some aspects, determining whether the patient has an increased risk for sepsis or septic shock includes determining that the NLR is greater than a first predetermined threshold, the WBC is outside a predetermined threshold range, and a monocyte population parameter is greater than a second predetermined threshold.
[0045] Each of the first predetermined threshold, the second predetermined threshold, and the predetermined threshold range can be selected by a person skilled in the art (including, for example, a clinician). Normal range values are known in the art and can vary slightly depending on the laboratory (e.g., due to testing methods or sample processing). In some aspects, the threshold can include multiple thresholds. In some aspects, the threshold range can include multiple ranges. For example, for each parameter, different thresholds can be provided for sepsis and septic shock.
[0046] In some aspects, the monocyte population parameter reflects the activation of monocytes. For example, the monocyte population parameter may preferably include a monocyte distribution width (MDW). When the monocyte population parameter includes MDW, the second predetermined threshold value may be 19, 20, 21, 22, 23, or 24. In such aspects, determining whether a patient has an increased risk of sepsis or septic shock includes determining that MDW is greater than a second predetermined threshold value. For example, the second predetermined threshold value may be 20, and determining whether a patient has an increased risk of sepsis or septic shock may include determining that MDW is greater than 20.
[0047] In some aspects, the lower limit of the threshold range for WBC is 3.4×10 9 Cells / L, 4×10 9 cells / L, 4.5×10 9 cells / L or 5×10 9 In some aspects, the upper limit of the threshold range for WBC is 9.6×10 9 cells / L, 10×10 9 Cells / L, 11×10 9 cells / L or 12×10 9 cells / L. Exemplary threshold ranges may include, for example, 4×10 9 Cells / L to 12×10 9 cells / L, 4.5×10 9 Cells / L to 11×10 9 Cells / L, 4×10 9 Cells / L to 11×10 9 Cells / L, 5×10 9 Cells / L to 10×10 9 In such aspects, determining whether a patient has an increased risk of sepsis or septic shock includes determining that the WBC is outside a threshold range. For example, the threshold range for WBC may be 4×10 9 Cells / L to 12×10 9 cells / L, and determining whether a patient is at increased risk for sepsis or septic shock can include determining that the WBC count is less than 4 × 10 9 Cells / L or greater than 12×10 9 Cells / L.
[0048] In some aspects, the first predetermined threshold is 6, 7, 8, 9, 10, 11, or 12. In such aspects, determining whether the patient has an increased risk of sepsis or septic shock can include determining that the NLR is greater than the first predetermined threshold. For example, the first predetermined threshold can be 10, and determining whether the patient has an increased risk of sepsis or septic shock can include determining that the NLR is greater than 10.
[0049] In some aspects, the method is an automated method. When the method is an automated method, the method may include using a data processing module to determine whether the patient has an increased risk of sepsis or septic shock. The data processing module may include a processor and a tangible non-transient computer-readable medium. The computer-readable medium may be programmed with any suitable computer application. For example, in some aspects, the computer-readable medium is programmed with such a computer application, which, when executed by a processor, causes the processor to compare NLR with a first predetermined threshold to provide a first comparison, compare a monocyte population parameter with a second predetermined threshold to provide a second comparison, compare WBC with a third predetermined threshold and a fourth predetermined threshold to provide a third comparison, and determine the risk of sepsis or septic shock based on the first comparison, the second comparison, and the third comparison. In such aspects, if the first comparison is higher than the first predetermined threshold, the second comparison is higher than the second predetermined threshold, and the third comparison is lower than the third predetermined threshold or higher than the fourth predetermined threshold, then determine that the risk of sepsis or septic shock indicates suspicion of sepsis or septic shock. In some aspects, the first predetermined threshold (i.e., the threshold of NLR) is 10. In some aspects, the monocyte population parameter includes the standard deviation of the monocyte volume, such as the monocyte distribution width (MDW), and the second predetermined threshold (ie, the threshold of MDW) is 20. In some aspects, the third predetermined threshold is 12×10 9 cells / L and the fourth predetermined threshold is 4×10 9 cells / L (i.e., the threshold range for WBC is 4×10 9 Cells / L to 12×10 9 cells / L). In some aspects, the automated method may also include indicating a suspicion of sepsis or septic shock in a sample test report. In some aspects, the automated method may include delivering a fluid-dynamically focused blood sample stream toward a cell interrogation region of an optical element; and measuring the current (DC) impedance of blood sample cells passing through the cell interrogation region individually with an electrode assembly; wherein the module determines the standard deviation of the volume of mononuclear cells based on the DC impedance measurement results of the blood sample cells.
[0050] In some aspects, the patient may present with non-specific discomfort. In some aspects, the patient may present with symptoms of a systemic inflammatory disorder.
[0051] In some aspects, the patient may preferably present to an emergency department.
[0052] In some aspects, the method further comprises administering a treatment for sepsis. Exemplary treatments for sepsis include administering antibiotic preparations, intravenous fluids, vasopressors, corticosteroids, insulin, analgesics, sedatives, or immune enhancing therapies, or a combination thereof.
[0053] In some aspects, the method may also include determining whether a treatment for sepsis has been administered, or determining whether a treatment for sepsis is successful.
[0054] Methods to rule out sepsis or septic shock
[0055] In some aspects, the present disclosure describes a method for excluding sepsis or septic shock in a patient. The method includes calculating the ratio (NLR) of neutrophils to lymphocytes from a blood sample of the patient; characterizing the white blood cell count (WBC) of the blood sample; and calculating the monocyte population parameter of the blood sample. The method also includes comparing WBC, monocyte population parameters and NLR with a threshold value or threshold range. For example, NLR can be compared with a first predetermined threshold, WBC can be compared with a predetermined threshold range, and monocyte population parameters can be compared with a second predetermined threshold. At least one of these comparisons is used to determine whether the patient has an increased risk of sepsis or septic shock. In some aspects, the method is an in vitro method.
[0056] In some aspects, determining whether a patient is not at risk of sepsis or septic shock includes determining whether at least one of WBC, monocyte population parameters, and NLR is less than a predetermined threshold or within a predetermined threshold range. In some aspects, determining whether a patient is not at risk of sepsis or septic shock includes determining that NLR is less than a first predetermined threshold and further determining that WBC is within a predetermined threshold range, or that the monocyte population parameter is less than a second predetermined threshold, or both. In some aspects, determining whether a patient is not at risk of sepsis or septic shock includes determining that NLR is less than a first predetermined threshold and further determining that the monocyte population parameter is less than a second predetermined threshold.
[0057] In some aspects, determining whether the patient is not at risk for sepsis or septic shock includes determining that the NLR is less than a first predetermined threshold, the WBC is within a predetermined threshold range, and the monocyte population parameter is less than a second predetermined threshold.
[0058] Each of the first predetermined threshold, the second predetermined threshold and the predetermined threshold range can be selected by those skilled in the art (including, for example, clinicians).Normal range values are known in the art and can be slightly different according to the laboratory (for example, due to test method or sample processing).In some aspects, the threshold value can include multiple threshold values.In some aspects, the threshold range can include multiple scopes.
[0059] In some aspects, the monocyte population parameter reflects the activation of monocytes. For example, the monocyte population parameter may include a monocyte volume measurement result. In such aspects, determining whether the patient is not at risk of sepsis or septic shock includes determining that the monocyte population parameter is less than a second predetermined threshold. In one example, the monocyte population parameter may preferably include a monocyte distribution width (MDW). When the monocyte population parameter includes MDW, the second predetermined threshold may be 19, 20, 21, 22, 23 or 24. In such aspects, determining whether the patient is not at risk of sepsis or septic shock includes determining that MDW is less than a second predetermined threshold. For example, the second predetermined threshold may be 20, and determining whether the patient is not at risk of sepsis or septic shock includes determining that MDW is less than 20.
[0060] In some aspects, the lower limit of the threshold range for WBC is 3.4×10 9 Cells / L, 4×10 9 cells / L, 4.5×10 9 cells / L or 5×10 9 In some aspects, the upper limit of the threshold range for WBC is 9.6×10 9 cells / L, 10×10 9 Cells / L, 11×10 9 cells / L or 12×10 9 cells / L. Exemplary threshold ranges may include, for example, 4×10 9 Cells / L to 12×10 9 cells / L, 4.5×10 9 Cells / L to 11×10 9 Cells / L, 4×10 9 Cells / L to 11×10 9 Cells / L, 5×10 9 Cells / L to 10×10 9 cells / L, etc. In such aspects, determining whether the patient is not at risk for sepsis or septic shock includes determining that the WBC is within a threshold range. For example, the threshold range for WBC may be 4×10 9 Cells / L to 12×10 9 cells / L, and determining whether a patient is not at risk for sepsis or septic shock can include determining that WBC is greater than 4×10 9 cells / L and less than 12×10 9 Cells / L.
[0061] In some aspects, the first predetermined threshold is 6, 7, 8, 9, 10, 11, or 12. In such aspects, determining whether the patient is not at risk for sepsis or septic shock includes determining that the NLR is less than the first predetermined threshold. For example, the first predetermined threshold can be 10, and determining whether the patient is not at risk for sepsis or septic shock includes determining that the NLR is less than 10.
[0062] In some aspects, the patient may present with non-specific discomfort. In some aspects, the patient may present with symptoms of a systemic inflammatory disorder.
[0063] In some aspects, the patient may preferably present to an emergency department.
[0064] Operating Environment and Exemplary Analyzers
[0065] Go to Figure 5 , according to some aspects described herein, an example operating environment 500 is depicted. In general, the example operating environment 500 includes a system that can facilitate the diagnosis, prediction and medical intervention actions described herein. The operating environment 500 is an example of a suitable environment and system architecture for implementing the embodiments of the present disclosure. Some embodiments can be implemented as a system, including one or more computers and associated networks and devices that execute methods or computer software applications on the system. Therefore, various aspects of the present disclosure can take the form of an embodiment combining software aspects and hardware aspects, which can all be generally referred to as "modules" or "systems" in this article. In addition, the method of the present disclosure can take the form of a computer application implemented in a computer-readable medium on which machine-readable application software is implemented. In this regard, a machine-readable storage medium can be any tangible medium that can contain or store software applications for use by a computing device.
[0066] Some aspects of the example operating environment 500 include at least one analyzer 502. An analyzer is a clinical diagnostic machine that is capable of measuring one or more anatomical or physiological characteristics of a sample, including: vital signs, metabolic measurements (also known as blood chemistry); cell counts; viral protein, viral gene, or microbial cell measurements; urine measurements; genomic features; or mass spectrometry and / or immunological measurements. As used herein, an analyzer includes a work unit or modular system in which two or more types of measurements are employed; for example, a work unit including blood chemistry and immunoassays. In some aspects, an analyzer may include a blood analyzer.
[0067] Some aspects of the example operating environment 500 include a network 504. The network 504 generally facilitates communication between the analyzer 502 and any other device communicatively coupled to the network 504. Thus, the network 504 may include access points, routers, switches, or any other network components generally understood to facilitate communication between devices. As an example, the network 504 may include one or more wide area networks, one or more local area networks, one or more public networks, one or more private networks, one or more telecommunication networks, or any combination thereof. In other words, the network 504 may include multiple networks, or one of multiple networks, but is depicted in a simplified form so as not to obscure the various aspects described herein.
[0068] Some aspects of the example operating environment 500 include a remote device 506. The remote device 506 can take a variety of forms, such as a personal computer (PC), a smart phone, a smart watch, a notebook computer, a mobile phone, a mobile device, a tablet computer, a wearable computer, a personal digital assistant (PDA), any combination of these demarcated devices, or any other device that can communicate directly or indirectly with an analyzer (e.g., analyzer 502) and / or a data storage device (e.g., data storage device 508). For example, in a particular aspect, the remote device 506 includes a workstation PC that can execute a local client application. The local client application can be communicatively connected to the analyzer 502, the data storage device 508, or both. For example, the local client application can be an application that facilitates user interaction with the analyzer 502. Local client application. In another example, the local client application can be an electronic medical record system application that facilitates user interaction with an electronic medical record system maintained by the data storage device.
[0069] Some aspects of the example operating environment 500 include one or more data storage devices 508. The data storage device 508 typically stores data, maintains data, and transmits data via the network 504. The data storage device 508 may include any combination of hardware, software, and firmware. For example, the data storage device 508 may include an electronic medical record (EMR) system. An EMR system may store medical information (e.g., demographic information, physical information, biological information, etc.) about multiple individuals. In other words, an EMR is a real-time, comprehensive collection of patient data, including medical history, doctor's notes, diagnoses, medications, allergies, immunizations, laboratory test results, and vital signs. The EMR system stores and maintains multiple EMRs.
[0070] In another example, the data storage device 508 may include a laboratory information system (LIS). A LIS is a software system that stores, processes, and manages data from laboratory analyzers and information about individuals including sample measurements. Laboratory test results (e.g., WBC and MDW) derived from individual biological samples may also be entered into the LIS by a laboratory professional manually, indirectly through laboratory middleware connected to one or more analyzers, or directly from the analyzer. In some aspects, the LIS system may add or modify patient data stored in the EMR system.
[0071] Go to Figure 6 , provides a depiction of an example analyzer 600 consistent with aspects described herein. Analyzer 600 depicts components that can be used in a system for measuring a sample (e.g., a blood sample). As will be appreciated by those skilled in the art, analyzers are available that rely on many principles to work, including electrical impedance, stain fluorescence analysis, cell image analysis, and light scatter analysis. In particular, many commercially available blood analyzers use a combination of these methods. For example, the Beckman Coulter DxH TM 900 blood analyzers use electrical impedance (also known as DC current) to determine cell size and count them, and use radio frequency (RF), light loss and light scattering to evaluate cell morphology and further distinguish cell subpopulations. For example, an exemplary system and method are described in U.S. Patent No. 5,125,737. It will be understood from the disclosure of U.S. Patent No. 5,125,737 that there is usually more than one way to distinguish cells in a blood sample. For example, cells can be distinguished based on volume (usually measured by impedance), or by light scattering, or by a combination of parameters. If distinguished by light scattering, light scattering at different angles can be used, such as low angle light scattering (LALS), axial light loss (ALL), upper middle angle light scattering (UMALS), etc. In some cases, cells similar in size and morphology can be best distinguished using a combination of different measurements, which can use a graph (e.g., one measurement on the x-axis, and another measurement on the y-axis) or a formula, such as a ratio or sum. As an example, eosinophils have several light scattering measurements similar to neutrophils, and it is difficult to distinguish based on any single measurement. However, by observing a combination of mid-angle light scatter (MALS), UMALS, and lower mid-angle light scatter (LMALS), eosinophils can be clearly distinguished from neutrophils as well as monocytes, lymphocytes, and basophils.
[0072] The DxH system uses high-speed, high-resolution analog-to-digital conversion using digital signal processing (DSP) circuitry to measure multiple parameters for each cellular event. DSP algorithms analyze cell data digitally, providing cell clarity and resolution. Different accuracy and labeling techniques are obtained by combining additional light scattering measurements with data analysis techniques to further define and separate cell populations. For example, in some cases, MALS can be transformed into modified rotated MALS (RMALS) parameters by mathematical transformation to eliminate overlap and produce different neutrophil, lymphocyte, monocyte and eosinophil populations, thereby achieving optimal analysis and visual confidence in the results. Current internal and visual differential data transformations include: RMALS (rotated MALS), opacity (conductivity minus size aspect), SOP (stretched opacity) and nonlinear AL2 transformation. The DxH system reports "VCS parameters".
[0073] Other blood analyzers, such as those manufactured by Abbott, Sysmex, and Mindray, use a cluster of differentiation (CD) system to differentiate between white blood cell populations. CD molecules can act in a variety of ways, usually acting as receptors or ligands; thereby initiating a signaling cascade that changes the behavior of the cell. Some CD proteins do not play a role in cell signaling, but have other functions, such as cell adhesion. Therefore, the CD system nomenclature, which is commonly used to identify cell markers, allows cells to be defined based on what molecules are present on the cell surface. There are more than 350 CD molecules identified as human. For example, monocytes can be identified with CD45+ and CD14+. Using fluorescently labeled antibodies, these cell markers can be used to sort cells. Fluorescence activated cell sorting (FACS) provides a method for sorting a heterogeneous mixture of cells into two or more containers based on the specific light scattering and fluorescence properties of each cell, sorting a single cell at a time. Fluorescence flow cytometry or FACS can also provide information about the cellular composition of labeled cells. For example, information about cell density or complexity can be obtained by measuring light scattered by the cells, and information about cell size and internal structure can be obtained by measuring the intensity of the cells' fluorescent signal. Fluorescence flow cytometry, or FACS, based systems report "FACS parameters."
[0074] There are thousands of possible combinations of computational relationships and sensor readings that may be associated with specific features of a blood sample, and once a cell subpopulation is identified, the specific cell subpopulation may be further characterized by one or more sensor readings (e.g., LALS, ALL, UMALS, LMALS, MALS, impedance, etc.) in addition to or in lieu of cytochemical staining, marker affinity, or other cell identification techniques. That is, a blood analyzer can often provide data on a cell subpopulation that is much richer than a simple count or ratio of these cells compared to other cell subpopulations in a sample. An example is monocyte distribution width (MDW), which is a calculation of the standard deviation of cell volumes within a monocyte subpopulation in a blood sample. This characteristic of the monocyte population is associated with sepsis, as described, for example, in PCT Application Nos. PCT / US2017 / 014708, PCT / US2020 / 041535, PCT / US2019 / 28486, PCT / US2020 / 041541, PCT / US2020 / 41548, and PCT / US2019 / 028487. The MDW can be determined by passing an electrical current through a blood sample and measuring the volume of a single cell passing through the measurement module based on the magnitude of the resulting impedance measurement (e.g., in Figure 6 The volume can also be measured by a system that transmits light through a blood sample and measures the resulting light scatter to determine the cell volume. In some cases, more than one characteristic of a cell subpopulation or the relationship between cell subpopulations can indicate the same or related conditions, such as viral infection, sepsis, anemia, leukemia, etc.
[0075] like Figure 6 As shown in , the analyzer 600 includes a transducer module 610 having a light or irradiation source, such as a laser 612 that emits a light beam 614. The laser 612 can be, for example, a 635 nm, 5 mW solid-state laser. In some cases, the analyzer 600 can include a focus alignment system 620 that adjusts the light beam 614 so that the resulting light beam 622 is focused and positioned at a cell interrogation region 632 of a circulation cell 630. In some cases, the circulation cell 630 receives a sample aliquot from the preparation system 602. A variety of fluidic mechanisms and techniques can be used to perform hydrodynamic focusing of the sample aliquot within the circulation cell 630.
[0076] In some cases, the aliquot is typically flowed through the cell interrogation zone 632 so that its components pass through the cell interrogation zone 632 one at a time. In some cases, the analyzer 600 may include a cell interrogation zone or other features of a transducer module or blood analysis instrument, such as those described in U.S. Patent Nos. 5,125,737; 6,228,652; 7,390,662; 8,094,299; 8,189,187 and 9,939,453, the contents of which are incorporated herein by reference for all purposes. For example, the cell interrogation zone 632 can be defined by a square cross-section measuring approximately 50×50 microns and having a length of approximately 65 microns (measured in the direction of flow). The circulation pool 630 may include an electrode assembly having a first electrode 634 and a second electrode 636 for performing DC impedance and / or RF conductivity measurements on cells passing through the cell interrogation zone 632. Signals from the electrodes 634, 636 can be sent to the analysis system 604. The electrode assembly can analyze the volume and conductivity properties of the cell using low-frequency current and high-frequency current, respectively. For example, low-frequency DC impedance measurements can be used to analyze the volume of each individual cell passing through the cell interrogation zone. High-frequency RF current measurements can be used to determine the conductivity of cells passing through the cell interrogation zone. Because the cell wall acts as a conductor for high-frequency current, the high-frequency current can be used to detect differences in the insulating properties of the cell components as the current passes through the cell wall and through the interior of each cell. High-frequency current can be used to characterize the nuclear and granular composition and the chemical composition of the cell interior.
[0077] Figure 6 The light source in has been described as a laser, however, the light source may alternatively or additionally include a xenon lamp, an LED lamp, an incandescent lamp, or any other suitable light source, including a combination of the same or different types of lamps (e.g., multiple LED lamps or at least one LED lamp and at least one xenon lamp). Figure 6As shown, for example, an incident light beam 622 illuminates cells passing through a cell interrogation zone 632, thereby causing light emanating from zone 632 to propagate (e.g., scatter, transmit) within an angular range α. The exemplary system is equipped with a sensor assembly that can detect light within one, two, three, four, five, or more angular ranges within the angular range α, including light associated with extinction or axial light loss metrics. As shown, light propagation 640 can be detected by a light detection assembly 650, which optionally has a light scatter detector unit 650A and a light scatter and / or transmission detector unit 650B. In some cases, the light scatter detector unit 650A includes a photosensitive area or sensor area for detecting and measuring upper mid-angle light scatter (UMALS), which is, for example, light scattered or otherwise propagated at angles within a range of 20 to 42 degrees relative to the beam axis. In some cases, UMALS corresponds to light propagating within an angular range of between 20 and 43 degrees relative to the axis of the incident light beam that illuminates cells flowing through the interrogation zone. Light scatter detector unit 650A may also include a photosensitive region or sensor area for detecting and measuring lower mid-angle light scatter (LMALS), such as light scattered or otherwise propagating at angles in the range of 10 to 20 degrees relative to the axis of the light beam. In some cases, LMALS corresponds to light propagating at angles in the range of between 9 and 19 degrees relative to the axis of the incident light beam illuminating cells flowing through the interrogation region.
[0078] The combination of UMALS and LMALS is defined as mid-angle light scattering (MALS), which can be light scattering or propagation at angles between 9 and 43 degrees relative to the axis of the incident light beam illuminating the cells flowing through the interrogation region. Those skilled in the art will appreciate that these angles (as well as other angles described herein) can vary based on the configuration of the interrogation, sensing, and analysis systems.
[0079] like Figure 6As shown, the light scatter detector unit 650A may include an opening 651 that enables low angle light scatter or propagation 640 to pass through the light scatter detector unit 650A and thereby reach the light scatter and transmission detector unit 650B and be detected by the light scatter and transmission detector unit 650B. According to some embodiments, the light scatter and transmission detector unit 650B may include a photosensitive area or sensor area for detecting and measuring lower angle light scatter (LALS), such as light scattered or propagated at an angle less than 5.1 degrees relative to the axis of the illumination beam. In some cases, LALS corresponds to light propagated at an angle less than 9 degrees relative to the axis of the incident light beam illuminating the cells flowing through the interrogation zone. In some cases, LALS corresponds to light propagated at an angle less than 10 degrees relative to the axis of the incident light beam illuminating the cells flowing through the interrogation zone. In some cases, LALS corresponds to light propagated at an angle of 1.9 degrees ± 0.5 degrees relative to the axis of the incident light beam illuminating the cells flowing through the interrogation zone. In some cases, LALS corresponds to light propagating at an angle of 3.0 degrees ± 0.5 degrees relative to the axis of an incident light beam illuminating cells flowing through the interrogation zone. In some cases, LALS corresponds to light propagating at an angle of 3.7 degrees ± 0.5 degrees relative to the axis of an incident light beam illuminating cells flowing through the interrogation zone. In some cases, LALS corresponds to light propagating at an angle of 5.1 degrees ± 0.5 degrees relative to the axis of an incident light beam illuminating cells flowing through the interrogation zone. In some cases, LALS corresponds to light propagating at an angle of 7.0 degrees ± 0.5 degrees relative to the axis of an incident light beam illuminating cells flowing through the interrogation zone. In each case, LALS can correspond to light propagating at an angle of 1.0 degree or greater. That is, LALs can correspond to light propagating at an angle between 1.0 degrees and 1.9 degrees; between 1.0 degrees and 3.0 degrees; between 1.0 degrees and 3.7 degrees; between 1.0 degrees and 5.1 degrees, between 1.0 degrees and 7.0 degrees, between 1.0 degrees and 9.0 degrees; or between 1.0 degrees and 10.0 degrees.
[0080] According to some embodiments, the light scattering and transmission detector unit 650B may include a photosensitive area or sensor area for detecting and measuring light that is axially transmitted through cells or propagated from irradiated cells at an angle of 0 degrees relative to the axis of the incident beam. In some cases, the photosensitive area or sensor area can detect and measure light that propagates axially from cells at an angle less than 1 degree relative to the axis of the incident beam. In some cases, the photosensitive area or sensor area can detect and measure light that propagates axially from cells at an angle less than 0.5 degrees relative to the axis of the incident beam. Such axial transmission or propagation of light measurement corresponds to axial light loss (ALL or AL2). As described in previously incorporated U.S. Patent No. 7,390,662, when light interacts with particles, some of the incident light changes direction through a scattering process (i.e., light scattering), and a portion of the light is absorbed by the particles. Both processes remove energy from the incident beam. When observed along the incident axis of the beam, light loss can be referred to as forward extinction or axial light loss. US Patent No. 7,390,662, column 5, line 58 to column 6, line 4, describes additional aspects of axial light loss measurement techniques.
[0081] Thus, the analyzer 600 provides a means for obtaining light propagation measurements, including light scatter and / or light transmission, of light emanating from illuminated cells of a biological sample at any of a variety of angles or within any of a variety of angular ranges, including ALL and a plurality of different light scatter or propagation angles. For example, the light detection assembly 650, including appropriate circuitry and / or processing units, provides a means for detecting and measuring UMALS, LMALS, LALS, MALS, and ALL.
[0082] Wires or other transmission or connectivity mechanisms can send signals from the electrode assembly (e.g., electrodes 634, 636), the light scatter detector unit 650A, and / or the light scatter and transmission detector unit 650B to the analysis system 604 for processing. For example, measured DC impedance, RF conductivity, light transmission, and / or light scatter parameters can be provided or sent to the analysis system 604 for data processing. In some cases, the analysis system 604 can include computer processing features and / or one or more modules or components that can evaluate the measured parameters, identify and enumerate the biological sample components, and associate a subset of data characterizing the biological sample elements with one or more features or parameters of interest. Some aspects of the analysis system 604 include an analysis engine, such as a computer program product that can be used to analyze the biological sample. Figure 8 Regarding description.
[0083] Additionally or alternatively, such as Figure 6As depicted, the analyzer 600 can generate or output a report 606 presenting the measurement results or calculated parameters obtained for the sample. The measurement results or calculated parameters obtained for the sample can include UMALS, LMALS, LALS, MALS, ALL, WBC, MDW, monocyte %, absolute lymphocyte count (ALC), lymphocyte %, eosinophil %, absolute neutrophil count (ANC), neutrophil % or any combination thereof. As further described herein, in some aspects, it can be particularly advantageous that the parameters include MDW, WBC, absolute lymphocyte count (ALC), absolute neutrophil count (ANC), and absolute lymphocyte count (ALC) and absolute neutrophil count (ANC) for calculating the ratio of neutrophils to lymphocytes.
[0084] In some cases, excess biological sample from the transducer module 610 can be directed to an external (or alternatively to an internal) waste system 608. In some cases, the analyzer 600 can include one or more features of a transducer module or blood analysis instrument, such as those described in previously incorporated U.S. Patent Nos. 5,125,737; 6,228,652; 8,094,299; 8,189,187; and 9,939,453.
[0085] Figure 7 An exemplary analyzer process 700 is schematically depicted, which may optionally utilize, for example, Figure 6 Analyzer 600. In this embodiment, at step 702, an individual's blood sample can be delivered to the analyzer, at which point the analyzer can prepare the sample for analysis. Once sample preparation is completed at step 704, the sample can pass through one or more measurement modules at step 706. The measurement modules of step 706 may include a conductivity module, a light scattering module, an RF module, or any combination thereof. Other modules can be used instead of or in addition to a conductivity module or a light scattering module. For example, a blood analyzer can use sensors to detect dyes or fluorescent markers, imaging, immunoassay markers, size sorting, or other methods to identify cells or other sample components. The sample measurement results can then be evaluated by a data processing module in step 708. In some aspects, once the sample measurement is completed, the measurement results can be displayed by a reporting module in step 710. Additionally or alternatively, once the sample measurement is completed, the measurement results can be transmitted to an analysis engine for further processing, such as Figure 8 Example analysis engine 800.
[0086] Figure 8An example analysis engine 800 is depicted in accordance with various aspects described herein. Aspects of the analysis engine 800 may be incorporated into an analyzer (e.g. Figure 6 The processing features and / or modules or components of the analysis system 604 depicted in FIG. Figure 5 506) executed by an application, or can be operated as an operating environment (e.g. Figure 5 An independent component of the operating environment 500) depicted in FIG.
[0087] Generally speaking, the analysis engine 800 evaluates a set of measurements or parameters, identifies and enumerates biological sample components, and associates a subset of data characterizing the biological sample elements with one or more features or parameters of interest. Thus, the analysis engine 800 includes a receiver module 804, an analyzer module 806, and a communicator module 808.
[0088] A receiver (e.g., receiver 802) typically collects measurements or calculated parameters based on analysis of individual samples. In some aspects, data (e.g., measurements or calculated parameters) may be received directly from a subsystem of the analyzer or from a data storage device. Receiver 802 may use any data collection technique known in the art.
[0089] The data analyzer 806 includes modules that include logical expressions for evaluating measurements and parameters received by the analysis engine 800. The logical expressions may include evaluating measurements received by the blood analyzer (e.g., Figure 5 The analyzer 502 described in the related Figure 6 The data analyzer 806 includes at least one of a sensitivity analyzer 810a, a decision rule analyzer 810b, and a risk analyzer 810c.
[0090] The sensitivity analyzer 810a includes a library of rules, models, and logical expressions in any combination that facilitate determining the probability and / or risk of one or more outcomes based on one or more parameters or features of a blood sample. In some aspects, potential outcomes can be associated with recommendations, treatments, or interventions. For example, where an individual's outcome corresponds to a risk of shock, a recommendation to transfer the individual to an ICU / intensive care unit can be associated therewith.
[0091] Decision rule analyzer 810b includes a decision rule library. A decision rule is a logical expression that compares an individual parameter or feature of a blood sample with a threshold value. Decision rule analyzer 810b collects one or more decision rules from the library to establish a logical expression that an analysis engine can evaluate. In one aspect, analyzer 810b can utilize a linear combination or two or more parameters. In combination, a decision rule can be used to determine the probability that an individual associated with a blood sample currently suffers from a disease (e.g., such as infection, including viral infection).
[0092] The risk analyzer 810c may include rules, models, logical expressions configured to predict a medical condition in any combination. For example, the risk analyzer module may characterize information received from the analyzer to determine the risk of an individual developing sepsis. Additionally, some aspects of the risk analyzer module may characterize information received from the analyzer to determine a probability of severity of sepsis.
[0093] In some aspects, the data analysis engine 800 can generate outputs in conjunction with the operation of one or more analyzer modules. For example, the decision rules maintained by the decision rule analyzer 810b can be used to determine whether an individual currently suffers from a disease, such as an infection. In response to the determination that an individual has a probability of infection above a certain threshold, some aspects of the data analysis engine 800 can activate the risk analyzer 810c to determine whether the individual is at a high risk of developing sepsis or septic shock. In response to the determination that an individual has a high risk of developing sepsis or septic shock, some aspects of the data analysis engine 800 can activate the sensitivity analyzer 810a to determine the recommended level of care or treatment. In alternative aspects, the sensitivity analyzer 810a can first identify that an individual is at risk of needing intensive care and / or at risk of in-hospital death, for example, within 48 hours of obtaining a blood sample, and then one or more of the decision rule analyzers 810b and / or risk analyzers 810c can be used to further determine.
[0094] The communicator 808 generally transmits the results of the analysis engine 800 to at least one predetermined destination. In some aspects, the predetermined destination may include a remote device (e.g., a local client of a laboratory information system or a local client of an electronic medical record system) that is executing Figure 5 Remote device 506 described in relation to this. In such aspects, the results may include: presentation of a visual display or audio signal providing care recommendations, authorization for discharge recommendations, diagnostic recommendations; or a reminder that the individual corresponding to the analyzed sample may develop sepsis or other serious condition.
[0095] In some aspects, the predetermined goal may include maintaining a data storage device for a laboratory information system or an electronic medical record system (e.g., Figure 5 In such aspects, the transmitted results may include inputting commands for the individual associated with the medical record of the analyzed sample. For example, the commands may include: transferring the individual to an intensive care unit, increasing medical personnel or equipment to monitor the individual, or specific testing or standard of care protocols.
[0096] As described in more detail above, the data analysis engine 800 includes at least one analyzer that processes measurements or parameters provided to the analysis engine. The processing may include rules, models, logical expressions configured to detect and / or predict medical conditions in any combination. For example, a decision rule analyzer (e.g., Figure 8 Some aspects of the decision rule analyzer 810b) described herein may include a procedure for characterizing information received from the analyzer to determine a probability that an individual has developed sepsis or is likely to develop sepsis. In particular, according to some aspects described herein, in Fig. 9 An exemplary method 900 for assessing sepsis or septic shock is depicted in . Method 900 may generally be described as a "decision rule" method, in which individual parameters or characteristics of a blood sample are considered against a threshold value for each parameter or characteristic.
[0097] As follows Fig.10
[00106] Additional or alternative embodiments of the methods described above that may be performed by a data analysis engine (eg, data analysis engine 800) include weighted scoring methods for parameters or features of a blood sample.
[0098] Hematologic evaluation of sepsis and septic shock
[0099] As described above, the analyzer can count and distinguish a variety of cells included in the blood sample. Some aspects of method 900 include characterizing blood cells as part of a complete blood count (CBC) in a blood sample at frame 902. CBC characterization can include characterizing a variety of different parameters. In one example, in a specific aspect of frame 902, method 900 includes determining the number (or count) of white blood cells present in each liter of blood. In another example, in a specific aspect of frame 902, method 900 includes determining the WBC percentage belonging to lymphocytes or the absolute number of white blood cells belonging to lymphocytes. In another example, in a specific aspect of frame 902, method 900 includes determining the WBC percentage belonging to neutrophils or the absolute number of WBC belonging to neutrophils. In yet another example, in a specific aspect of frame 902, method 900 includes determining monocyte parameters, including, for example, monocyte distribution width (MDW). Based on the collected information, the analyzer can determine, for example, a white blood cell count (WBC), a percentage of lymphocytes, a percentage of neutrophils, a lymphocyte count, a neutrophil count, a ratio of neutrophils to lymphocytes (NLR), or a monocyte distribution width (MDW), or any combination thereof. For example, at box 902, the method can also include determining an absolute neutrophil count and an absolute lymphocyte count by the analyzer, and using these values to determine the NLR. In an alternative aspect of box 902, the analyzer engine can query the individual's medical record to obtain a data value corresponding to the latest value of a white blood cell count (WBC), a percentage of lymphocytes, a percentage of neutrophils, a lymphocyte count, a neutrophil count, a ratio of neutrophils to lymphocytes (NLR), or a monocyte distribution width (MDW), or a combination thereof.
[0100] At decision block 904, the analyzer further determines whether the NLR determined in block 902 is greater than a first predetermined threshold (e.g., comprising 6, 7, 8, 9, 10, 11, or 12). In some aspects, if the NLR is greater than the first predetermined threshold (e.g., 10, such as Fig. 9 ), the sample test report may indicate suspicion of sepsis or septic shock, as shown in block 912 .
[0101] Additionally or alternatively (if it is determined that the NLR is less than the first predetermined threshold), the method can proceed to decision block 906. Decision block 906 includes determining whether the number of white blood cells per liter in the patient's blood is within a threshold range. The lower limit of the threshold range for WBCs can be, for example, 3.4×10 9 Cells / L, 4×10 9 cells / L, 4.5×10 9 cells / L or 5×10 9 cells / L; the upper limit of the threshold range can be 9.6×10 9cells / L, 10×10 9 Cells / L, 11×10 9 cells / L or 12×10 9 cells / L. Exemplary threshold ranges may include, for example, 4×10 9 Cells / L to 12×10 9 cells / L, 4.5×10 9 Cells / L to 11×10 9 Cells / L, 4×10 9 Cells / L to 11×10 9 Cells / L, 5×10 9 Cells / L to 10×10 9 In some aspects, if the white blood cell count (WBC) is less than the lower limit of the threshold range (e.g., 4×10 9 Cells / L, e.g. Fig. 9 ) or greater than the upper limit of the threshold range (e.g., 12×10 9 Cells / L, e.g. Fig. 9 ), then the sample test report (such as in Fig.11 ) may indicate suspicion of sepsis or septic shock, as shown in box 912.
[0102] Additionally or alternatively (if it is determined that the NLR is less than the first predetermined threshold and the WBC is outside the threshold range), the method can proceed to decision block 908. At decision block 908, the method includes determining whether the monocyte distribution width (MDW) value in the blood sample is greater than a second predetermined threshold (including, for example, 19, 20, 21, 22, 23, or 24). In other words, the analyzer determines whether the standard deviation of the monocyte volume distribution reported by the MDW value determined in block 902 is greater than the second predetermined threshold in the monocytes counted by the analyzer. In some aspects, if the MDW is greater than the second predetermined threshold (e.g., 20, such as Fig. 9 ), the sample test report may indicate suspicion of sepsis or septic shock, as shown in block 912 .
[0103] If it is determined that NLR is greater than a first predetermined threshold; WBC is outside a threshold range; and MDW is less than a second predetermined threshold, method 900 may proceed to block 910. At block 910, the analyzer may determine that sepsis or septic shock is unlikely.
[0104] Additionally or alternatively, although not in Fig. 9 However, if more than one (e.g., 2 or more parameters) is greater than a predetermined threshold or threshold range, the sample test report may indicate a suspicion of sepsis or septic shock (e.g., Fig. 9 912 in FIG.
[0105] At box 912, the analyzer may generate a suspicious message. In some cases, the suspicious message may include a mark, message, or other signal on the test report to indicate possible sepsis or septic shock to a clinician or researcher. In some aspects, the suspicious message may include an audio or visual message transmitted to a remote device indicating that an individual associated with the sample may have a viral infection. The indication may be provided on a screen, such as a display of a blood analyzer, a laboratory information system (LIS), or an electronic medical record (EMR), or may be provided in a printout, fax, email, or other digital or hard copy report of the hematology test results.
[0106] In some aspects, a suspected sepsis or septic shock message can prompt additional testing of the patient, including, for example, additional standard of care sepsis testing.
[0107] In some aspects, the suspected sepsis or septic shock message can prompt the individual for treatment appropriate for possible sepsis or septic shock 914. In some aspects, the suspected sepsis or septic shock message can prompt a clinician user that the patient is at risk for sepsis or septic shock. Exemplary treatments for sepsis or septic shock can include administration of antibiotic preparations, intravenous fluids, vasopressors, corticosteroids, insulin, analgesics, sedatives, or immune enhancement therapies, or combinations thereof.
[0108] As further described herein, it may be advantageous for the analyzer to further include other clinical data. Such clinical data may be incorporated using the same analyzer or an additional analyzer. The incorporation of other clinical data may further include the use of an algorithm. Exemplary additional clinical data may include patient demographics, medical history, chief complaint, and vital signs, etc. In some aspects, the clinical data may preferably be clinical data available to a clinician and / or analyzer prior to the CBC result.
[0109] Additional or alternative embodiments of the method performed by the data analysis engine (e.g., data analysis engine 800) may include a weighted scoring method for the parameters or features of the blood sample. For example, the data analysis engine may perform operations or processes to perform Fig.10.Similar to method 900, aspects of method 1000 include characterizing blood cells as part of a complete blood count (CBC) in a blood sample at box 1002. CBC characterization may include characterizing a variety of different parameters. In one example, in a specific aspect of box 1002, method 1000 includes determining the number (or count) of white blood cells present in each liter of blood. Alternatively or additionally, in a specific aspect of box 1002, method 1000 includes determining the percentage of WBC belonging to lymphocytes or the absolute number of white blood cells belonging to lymphocytes. In another example, in a specific aspect of box 1002, method 1000 includes determining the percentage of WBC belonging to neutrophils or the absolute number of WBC belonging to neutrophils. In yet another example, in a specific aspect of box 1002, method 1000 includes determining monocyte parameters, including, for example, monocyte distribution width (MDW). Based on the collected information, the analyzer can determine, for example, a white blood cell count (WBC), a percentage of lymphocytes, a percentage of neutrophils, a lymphocyte count, a neutrophil count, a ratio of neutrophils to lymphocytes (NLR), or a monocyte distribution width (MDW), or any combination thereof. For example, at box 1002, the method can also include determining an absolute neutrophil count and an absolute lymphocyte count by the analyzer, and using these values to determine the NLR. In an alternative aspect of box 1002, the analyzer engine can query the individual's medical record to obtain a data value corresponding to the latest value of a white blood cell count (WBC), a percentage of lymphocytes, a percentage of neutrophils, a lymphocyte count, a neutrophil count, a ratio of neutrophils to lymphocytes (NLR), or a monocyte distribution width (MDW), or a combination thereof.
[0110] In a particular embodiment of method 1000, the data analysis engine discretizes one or more of the values (or counts) determined during characterization of the blood sample. For example, MDW is discretized at block 1004, NLR is discretized at block 1006, and WBC is discretized at block 1008. For example, the discretization of WBC or any other parameter may be by truncating, rounding, or otherwise approximating the measured values to discrete counts using, for example, the Euler-Maruyama method, zero-order hold, or any other suitable method. Fig.10As depicted in , each discretized value is analyzed with a set of decision rules 1010 associated with each of the discretized parameters. Decision rules 1010 depict example parameter ranges for determining MDW values, NLR values, and WBC values. For example, according to the weighted scoring decision rule of the data analysis engine, MDW values between 0 and 20 are scored as 0 (zero), values greater than 20 and less than or equal to 25 are scored as 2, and values greater than 25 are scored as 4. For another example, according to the weighted scoring decision rule of the data analysis engine, NLR values between 0 and 6 are scored as 0 (zero), values greater than 6 and less than or equal to 10 are scored as 2, and values greater than 10 are scored as 4. For another example, according to the weighted scoring decision rule of the data analysis engine, WBC values between 0 and 4 are scored as 1, values greater than 4 and less than or equal to 12 are scored as 0, values greater than 12 and less than or equal to 15 are scored as 1, and values greater than 15 are scored as 2. Although other weighted decision rules are contemplated, this discretization is determined based on a univariate assessment of the relationship between parameters and sepsis outcomes from multiple observational studies (e.g., descriptive statistics and graphs). A logistic regression analysis was performed with sepsis (Sepsis-3 criteria) as the dependent variable and the discretized leukocyte parameters as the independent variables. The odds ratio for each of the discrete categories of the leukocyte parameters was identified, and the weights of the point system were defined based on the odds ratio. For example, the goal is to convert these odds ratios (weights) into a simple scoring system between 0 and a set maximum value. In the depicted example, the maximum point is set to a value of 10. Therefore, the set of odds ratios is summed (e.g., 2.77+5.39+2.36+4.52+1.10+1.89+2.97=12.9) and scaled to the desired maximum value (e.g., 10 / 12.9) to obtain a conversion factor of 0.78. Each odds ratio is multiplied by the conversion factor (0.78) and rounded to the nearest integer to produce the index points depicted in the decision rule 1010.
[0111] In some embodiments of method 1000, an analyzer (e.g., data analysis engine 800) classifies the risk associated with the blood sample based on a decision rule. The risk classification includes a plurality of potential categories based on a calculated sum of index points for each of the analysis parameters. Fig.10 As depicted in , the low risk category 1012 may include patients whose blood samples have a cumulative score less than or equal to 3; the medium risk category 1014 may include patients whose blood samples have a cumulative score greater than 3 and less than or equal to 7; and the high risk category 1016 may include patients whose blood samples have a cumulative score greater than 7.
[0112] Similar to method 900, method 1000 includes generating a suspicious message. In some cases, the suspicious message may include a mark, message or other signal on the test report to indicate possible sepsis or septic shock to a clinician or researcher. In some aspects, the suspicious message may include an audio or visual message transmitted to a remote device indicating that an individual associated with the sample may have a viral infection. The indication may be provided on a screen, such as a display of a blood analyzer, a laboratory information system (LIS), or an electronic medical record (EMR), or may be provided in a printout, fax, email, or other digital or hard copy report of a hematology test result.
[0113] In some aspects, a suspected sepsis or septic shock message can prompt additional testing of the patient, including, for example, additional standard of care sepsis testing.
[0114] In some aspects, the suspected sepsis or septic shock message can prompt an individual for treatment appropriate for possible sepsis or septic shock. In some aspects, the suspected sepsis or septic shock message can prompt a clinician user that the patient is at risk for sepsis or septic shock. Exemplary treatments for sepsis or septic shock can include administration of antibiotic preparations, intravenous fluids, vasopressors, corticosteroids, insulin, analgesics, sedatives, or immune enhancement therapies, or combinations thereof.
[0115] Analyzers and Algorithms
[0116] As described above, the analysis engine may include a risk analyzer configured to process measurements or parameters provided to the analysis engine. The risk analyzer may include rules, models, logical expressions configured to detect and / or predict medical conditions in any combination. A data analyzer (e.g., Figure 8 The data analyzer 806 of the present invention may include a machine learning algorithm, including, for example, a decision tree-based classifier, a simple logistic classifier, a neural network, a logistic regression algorithm, etc. The processing may be used to help screen for sepsis or septic shock in a patient, or to rule out sepsis or septic shock in a patient. Additionally or alternatively, the machine learning algorithm may be used to calculate the parameters and rules of the weighted scoring method (e.g., as described in reference to Fig.10 1000 as described herein).
[0117] In some aspects, the machine learning algorithm processes input to provide output data. The input may include WBC, monocyte population parameters and / or NLR (or whether WBC, monocyte population parameters and / or NLR exceed a threshold value or a threshold range), and the output may include information indicating whether the patient has an increased risk of sepsis or septic shock. In some aspects, the input may include all of WBC, monocyte population parameters and NLR. In some aspects, the input may include information about whether any one of WBC, monocyte population parameters and NLR exceeds a threshold value or a threshold range. The output data may include a numerical value specifying a risk of sepsis or septic shock. The output data may also include the rationale for specifying a numerical value of a risk of sepsis or septic shock. The rationale may include, for example, a text-based message that identifies a risk of sepsis associated with a patient based on the output data, and includes information about a risk based on a predefined risk category (e.g., by executing as described above and in Fig.10 Contextual information about the relative severity of the risk (e.g., “low,” “low risk,” “medium,” “medium risk,” “high,” or “high risk”) obtained by the method 1000 depicted in FIG. 1 .
[0118] In some aspects, the output data can be subjected to additional transformations such as described by fixed functions to provide index scores. In some aspects, the index score can specify the probability that a patient has an increased risk of sepsis or septic shock. Alternatively, the index score can specify the probability that a patient does not have an increased risk of sepsis or septic shock. In some aspects, the index score can be the result of a weighted scoring method. In some aspects, the index score can be the result of comparing a parameter (e.g., a monocyte population parameter and / or NLR) to more than one threshold or comparing a parameter (e.g., WBC) to more than one threshold range.
[0119] In a fast-paced ED environment, rapid simultaneous interpretation of WBC, NLR, and MDW would be challenging, and processing in at least one analyzer could provide a more immediate interpretation to clinical care providers. In addition, additional precision is likely to be achieved by algorithms that incorporate other clinical data (e.g., patient demographics, medical history, chief complaints, and vital signs), all of which are available before CBC results are available. (Levin et al. Ann Emerg Med. 2018; 71(5): 565-574.e2).
[0120] For example, a sensitivity analyzer (e.g., Figure 8Some aspects of the sensitivity analyzer 810a) described may include a program that characterizes the information received from the analyzer to determine the sensitivity of the individual. In some aspects, the sensitivity analyzer may include such a program that characterizes the information received from the analyzer to: identify individuals to be discharged and / or assess whether the individual is responsive to care. In some aspects, the sensitivity analyzer may include such a program that characterizes the information received from the analyzer to: assess the severity of infection, and / or determine whether the individual is at risk of sepsis or shock. In some aspects, the sensitivity analyzer may include such a program that characterizes the information received from the analyzer to: stratify the risks associated with febrile neonates, assess or predict the risk of systemic infection, assess or predict whether the individual is at risk of presenting a high inflammatory state, distinguish whether an individual suspected of infection suffers from a viral infection, distinguish whether an individual suspected of infection suffers from a bacterial infection, distinguish whether antibiotic treatment should be provided, distinguish whether an individual is experiencing respiratory exacerbations such as cystic fibrosis associated with inflammation and / or infection, assess the severity of infection in immunocompromised individuals, or a combination thereof.
[0121] In certain aspects, systems and methods are provided for assessing the sensitivity of an individual. In some systems, most individuals arriving at an emergency department (ED) have an uncertain expected clinical course. For example, in some cases, most individuals entering the ED may be stable, and the ED will require various types of resources (e.g., laboratory tests and / or imaging) to investigate or treat the individual. In some cases, such individuals with an uncertain expected clinical course may be preliminarily classified as emergency severity index level 3. The time required for investigating individuals with an uncertain expected clinical course results in extended waiting time and residence time, and may be the cause of ED or nursing inefficiency. In addition, due to the overlapping symptoms of a variety of diseases including conditions associated or unassociated with infection, it may be challenging to diagnose an individual seeking care in the ED. Extended waiting time and extended diagnosis time may lead to adverse consequences.
[0122] The systems and methods disclosed herein can alleviate one or more of the above problems. For example, in certain aspects, the systems and methods disclosed herein can assess the sensitivity of an individual. In such aspects, evaluating or assessing the sensitivity of an individual can identify an individual who may need to increase care at an early stage, for example, an individual with sepsis or septic shock or with a risk or increased risk of sepsis or septic shock. These individuals can then be more effectively transferred to an appropriate care room, such as an intensive care facility (e.g., an intensive care unit (ICU)). In the same or alternative aspects, by identifying an individual with a risk of sepsis or severe sepsis at an early stage via the methods disclosed herein, an additional standard of care sepsis test can be arranged.
[0123] In various aspects, the systems and methods disclosed herein can identify individuals to be discharged. For example, in certain aspects, the MDW value (alone or in combination with WBC and / or NLR) can be compared with one or more predetermined criteria to identify the individual as a candidate to be discharged. In various aspects, parameter values can be obtained on multiple blood samples during care or observation. In such aspects, identifying individuals to be discharged can help free up hospital resources, and / or allocate hospital resources more efficiently.
[0124] For example, as in Fig.11 Described in and incidentally referred to Figures 5 to 10 , analyzer 1102 can process and analyze a biological sample (e.g., blood) and generate output data. Analyzer 1102 can be a hematology instrument (e.g., analyzer 600) or any other laboratory equipment configured to determine measurements or parameters related to blood or its components. Output data from analyzer 1102 can include UMALS, LMALS, LALS, MALS, ALL, WBC, MDW, monocyte %, ALC, lymphocyte %, eosinophil %, ANC, neutrophil %, neutrophil to lymphocyte ratio, or any combination thereof. A data analyzer (e.g., data analyzer 806) coupled to or remotely executed by analyzer 1102 accesses the output data. The data analyzer can analyze the data (e.g., as described in conjunction with Figures 7 to 10 For example, data analyzer 806 can generate a sepsis risk score using a weighted scoring approach based on a rule set of parameters and measurements determined by analyzer 1102. In addition, communicator (e.g., Figure 8 The communicator 808 of the data analyzer sends the risk score generated by the data analyzer to a data storage device (e.g., Figure 5 The data storage device 508 maintains an electronic medical record 1104 of the patient associated with the biological sample. The risk score can be added to the electronic medical record 1104 in a machine-understandable format (with executable instructions defining a maximum score, a reference range, or both).
[0125] In certain embodiments, the executable instructions include conditional instructions that are triggered in response to a predetermined action. For example, the remote device 506 may execute a local or remote application that provides access to the electronic medical record 1104 stored by the data storage device 508. In response to the application requesting a complete blood count (CBC) of the patient (e.g., report data 1106), the instructions may trigger the insertion of the risk score identifier 1108, the risk score 1108a, and the reference range 1108b.
[0126] In another embodiment, the executable instructions trigger an automated message on a remote device 506 executing an application that provides access to the electronic medical record 1104 stored by the data storage 508 in response to the risk score exceeding a predetermined threshold.
[0127] Computer-implemented methods
[0128] In a first aspect, the present disclosure provides a computer-implemented method comprising obtaining object value data of a patient with a computing device. The object value data comprises at least one of a neutrophil-to-lymphocyte ratio (NLR) of a blood sample from the patient, a white blood cell count (WBC) of a blood sample from the patient, and a monocyte population parameter of a blood sample from the patient. The computer-implemented method also comprises determining, with the computing device, whether the patient has an increased risk of sepsis or septic shock by using the object value data of the patient.
[0129] In a second aspect, the present disclosure provides a computer-implemented method comprising obtaining object value data of a patient with a computing device. The object value data comprises at least one of a neutrophil to lymphocyte ratio (NLR) from a blood sample of the patient, a white blood cell count (WBC) from a blood sample of the patient, and a monocyte population parameter from a blood sample of the patient. The computer-implemented method further comprises determining with the computing device whether the patient is not at risk of sepsis or septic shock.
[0130] In some aspects, the object value data includes a neutrophil to lymphocyte ratio (NLR) from a blood sample of the patient, a white blood cell count (WBC) from a blood sample of the patient, and a monocyte population parameter from a blood sample of the patient.
[0131] In some aspects, the monocyte population parameter preferably includes monocyte distribution width (MDW).
[0132] The patient's object value data may also include one or more additional parameters, including, for example, patient vital signs, such as the patient's blood pressure, the patient's blood oxygen level, the patient's heart rate, etc. Alternatively or additionally, the patient's object value data may also include one or more of lymphocyte percentage, neutrophil percentage, lymphocyte count, and neutrophil count.
[0133] Determining with a computing device whether a patient has an increased risk of sepsis or septic shock may be performed using at least one trained machine learning algorithm. Determining with a computing device whether a patient is not at risk of sepsis or septic shock may be performed using at least one machine learning algorithm. Thus, the method according to the first aspect of the present disclosure and / or the method according to the second aspect of the present disclosure may be at least partially implemented as a trained machine learning algorithm or any other artificial intelligence based algorithm.
[0134] The machine learning algorithm may include a trained artificial intelligence-based algorithm. For example, the machine learning algorithm may include at least one decision tree, at least one neural network, at least one gradient boosting algorithm, and / or at least one logistic regression algorithm. In some aspects, the machine learning algorithm consists of a decision tree, a neural network, a gradient boosting algorithm, or a logistic regression algorithm.
[0135] The obtained object value data of the patient can be processed by means of a trained classifier of the computing device. For example, the computing device may include a classifier or a classifier circuit system, which may include a trained machine learning algorithm, a trained gradient boosting algorithm, or any other AI-based algorithm or circuit system. The classifier may be part of the control circuit system of the computing device, or may be implemented as a separate classifier circuit system in the computing device.
[0136] Exemplarily, determining whether a patient has an increased risk of sepsis includes processing the patient's object value data by using a machine learning algorithm. For example, the obtained patient's object value data can be processed by means of a trained classifier of a computing device. According to an embodiment of the second aspect of the present disclosure, determining whether a patient is not at risk of sepsis or septic shock includes processing the patient's object value data by using a machine learning algorithm. Therefore, in particular, according to the present disclosure, the patient's object value data can be an input to a trained machine learning algorithm.
[0137] In some embodiments of the first aspect of the present disclosure, determining whether the patient has an increased risk of sepsis or septic shock includes generating output data. According to some embodiments of the second aspect of the present disclosure, determining whether the patient is not at risk of sepsis or septic shock includes generating output data. In particular, according to the present disclosure, generating output data can be performed by processing the object value data of the patient using a machine learning algorithm. In some embodiments of the first aspect of the present disclosure, the output data includes information indicating whether the patient has an increased risk of sepsis or septic shock. According to some embodiments of the second aspect of the present disclosure, the output data includes information indicating whether the patient is not at risk of sepsis or septic shock, including generating output data.
[0138] According to the present disclosure, the output data may include a numerical value. For example, the numerical value may be between 0 and 1, or between 0 and 10, or a value contained within any other standardized range, and may specify the risk of sepsis or septic shock such that a larger value of the numerical value corresponds to a higher risk of sepsis or septic shock. Alternatively, the numerical value may specify the risk of sepsis or septic shock such that a larger value of the numerical value corresponds to a lower risk of sepsis or septic shock.
[0139] The output data may also include a rationale for assigning a numerical value for the risk of sepsis or septic shock. The rationale may include, for example, a text-based message.
[0140] According to the present disclosure, the output data can be subjected to additional transformations, such as described by fixed functions, to provide an index score. According to a first aspect of the present disclosure, the index score can specify the probability that a patient has an increased risk of sepsis or septic shock. In some embodiments of the second aspect of the present disclosure, the index score can specify the probability that a patient does not have a risk of sepsis or septic shock. In some aspects, the index score can be the result of a weighted scoring method. In some aspects, the index score can be the result of comparing a parameter (e.g., a monocyte population parameter and / or NLR) to more than one threshold or comparing a parameter (e.g., WBC) to more than one threshold range.
[0141] In particular, a machine learning algorithm can be trained by using a reference data set indicating reference object values associated with one or more reference patients. The reference data set can include a plurality of reference object value data. For example, each of the plurality of reference object value data includes at least one of: a neutrophil to lymphocyte ratio (NLR) of a blood sample from a corresponding reference object; a white blood cell count (WBC) of a blood sample from a corresponding reference object, and a monocyte population parameter of a blood sample from a corresponding reference object.
[0142] In some aspects, each reference subject value data in the plurality of reference subject value data comprises a neutrophil to lymphocyte ratio (NLR) from a blood sample of the corresponding reference subject, a white blood cell count (WBC) from a blood sample of the corresponding reference subject, and a monocyte population parameter from a blood sample of the corresponding reference subject.
[0143] The reference data set can be used, for example, to train and / or serve as a training data set for a machine learning algorithm, an AI-based algorithm, and / or a classifier of a computing device. For example, a trained machine learning algorithm, an AI-based algorithm, and / or a classifier may include a plurality of parameters whose values are determined during training using the reference data set. For example, a computing device may be trained using raw reference data associated with one or more reference objects. Additionally or alternatively, a machine learning algorithm may be used to calculate parameters and rules for a weighted scoring method (e.g., such as by performing the above-described and Fig.10 ) obtained by the method 1000 depicted in .
[0144] Each of the plurality of reference subject value data may include sepsis information for the reference subject. According to the first aspect of the present disclosure, the sepsis information for the reference subject indicates whether the corresponding reference subject has an increased risk of sepsis or septic shock. In some embodiments of the second aspect of the present disclosure, the reference subject indicating whether the corresponding reference subject is not at risk of sepsis or septic shock includes generating output data. During training, the sepsis information included in at least a portion of the plurality of reference subject value data may be used to evaluate a loss function that is used, e.g., minimized, during training of a machine learning algorithm.
[0145] According to the present disclosure, the method may include determining and / or deriving at least a portion of a reference data set by using raw reference data associated with one or more reference patients. The raw reference data may include NLR from a blood sample of a reference subject, WBC from a blood sample of a reference subject, a monocyte population parameter from a blood sample of a reference subject, sepsis information of a reference subject.
[0146] According to the present disclosure, "obtaining data with a computing device" or "obtaining object value data with a computing device" may include accessing data or object value data by a computing device. Alternatively, "obtaining data with a computing device" or "obtaining object value data with a computing device" or "obtaining object value data of a patient with a computing device" may include generating data or object value data, i.e., creating data or object value data based on one or more inputs. In yet another example, "obtaining data with a computing device" or "obtaining object value data of a patient with a computing device" may include accessing a first portion of data or object value data, and generating a second portion of the data or object value data from the first portion of the data or object value data.
[0147] In the present disclosure, "accessing data by a computing device" may include, for example, obtaining data from at least one memory of the computing device, from the memory of another computing device, or from another remote data storage device (database, auxiliary memory, cloud storage device, etc.). Therefore, in some cases, obtaining data may include downloading data. Exemplarily, the computing device may obtain data in response to a user command and / or a notification sent by another computing device. Additionally or alternatively, "accessing data by a computing device" may include, for example, receiving data from a user or another computing device. These two options are not mutually exclusive. For example, "accessing data by a computing device" may include receiving data, storing data in the memory of the computing device, and obtaining data by accessing the memory.
[0148] In the present disclosure, obtaining the object value data of the patient may include calculating the NLR of the blood sample from the patient, characterizing the WBC of the blood sample from the patient, and / or calculating the monocyte population parameter of the blood sample from the patient. Obtaining the object value data of the patient may additionally or alternatively include obtaining data providing information about the relationship between the NLR of the blood sample from the patient, the WBC of the blood sample from the patient, and / or the monocyte population parameter of the blood sample from the patient and the corresponding threshold value or threshold range.
[0149] The invention is defined in the claims. However, a non-exhaustive list of non-limiting exemplary aspects is provided below. Any one or more of the features of these aspects may be combined with any one or more of the features of another example, embodiment or aspect described herein.
[0150] Exemplary Aspects
[0151] Aspect A1 is a method for screening for sepsis or septic shock in a patient, the method comprising: calculating a neutrophil to lymphocyte ratio (NLR) of a blood sample from the patient; characterizing a white blood cell count (WBC) of the blood sample; calculating a monocyte population parameter of the blood sample; comparing the NLR to a first predetermined threshold, the WBC to a predetermined threshold range, and the monocyte population parameter to a second predetermined threshold; and determining whether the patient has an increased risk of sepsis or septic shock.
[0152] Aspect A2 is the method of Aspect A1, wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining that the NLR is greater than a first predetermined threshold, the WBC is outside a predetermined threshold range, or a monocyte population parameter is greater than a second predetermined threshold, or a combination thereof.
[0153] Aspect A3 is the method of Aspect A1 or A2, wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining that the NLR is greater than a first predetermined threshold, the WBC is outside a predetermined threshold range, and the monocyte population parameter is greater than a second predetermined threshold.
[0154] Aspect A4 is the method of any of Aspects A1 to A3, wherein the monocyte population parameter reflects monocyte activation.
[0155] Aspect A5 is the method of any one of Aspects A1 to A4, wherein the monocyte population parameter comprises monocyte distribution width (MDW).
[0156] Aspect A6 is the method of Aspect A5, wherein the second predetermined threshold is 19, 20, 21, 22, 23 or 24, and wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining that the MDW is greater than the second predetermined threshold.
[0157] Aspect A7 is the method of Aspect A6, wherein the second predetermined threshold is 20, and wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining that the MDW is greater than 20.
[0158] Aspect A8 is the method of any one of Aspects A1 to A7, wherein the lower limit of the threshold range of WBC is 3.4×10 9 Cells / L, 4×10 9 cells / L, 4.5×10 9 cells / L or 5×10 9 cells / L; and the upper limit of the threshold range is 9.6×10 9 cells / L, 10×10 9 Cells / L, 11×10 9 cells / L or 12×10 9 cells / L, and wherein determining whether the patient has an increased risk of sepsis or septic shock includes determining that the WBC is outside a threshold range.
[0159] Aspect A9 is the method of Aspect A8, wherein the threshold range is 4×10 9 Cells / L to 12×10 9 cells / L, and wherein determining whether the patient has an increased risk of sepsis or septic shock includes determining that the WBC is less than 4×10 9 Cells / L or greater than 12×10 9 Cells / L.
[0160] Aspect A10 is the method of any one of Aspects A1 to A7, wherein the first predetermined threshold is 6, 7, 8, 9, 10, 11 or 12, and wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining that the NLR is greater than the first predetermined threshold.
[0161] Aspect A11 is the method of Aspect A10, wherein the first predetermined threshold is 10, and wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining that the NLR is greater than 10.
[0162] Aspect A12 is the method of any of Aspects A1 to A11 , wherein the patient presents with non-specific discomfort.
[0163] Aspect A13 is the method of any of Aspects A1 to A12, wherein the patient exhibits symptoms of a systemic inflammatory disorder.
[0164] Aspect A14 is the method of any of Aspects A1 to A13, wherein the patient presents to an emergency department.
[0165] Aspect A15 is the method according to any of aspects A1 to A14, wherein the method is an in vitro method.
[0166] Aspect A16 is the method of any of Aspects A1 to A15, wherein the method further comprises administering a treatment for sepsis.
[0167] Aspect A17 is the method of Aspect A16, wherein administering a treatment for sepsis comprises administering an antibiotic preparation, an intravenous fluid, a vasopressor, a corticosteroid, insulin, an analgesic, a sedative, or an immune enhancing therapy, or a combination thereof.
[0168] Aspect A18 is the method of Aspect A16 or A17, wherein the method further comprises determining the success of the treatment of sepsis.
[0169] Aspect A19 is the method of any one of Aspects A1 to A18, wherein the method further comprises discretizing one or more of the NLR, WBC, and monocyte population parameters to provide discretized values of one or more of the NLR, WBC, and monocyte population parameters; analyzing the discretized values of one or more of the NLR, WBC, and monocyte population parameters using a decision rule set; defining weights for the point system based on odds ratios; and generating index points that can be added to provide an index score.
[0170] Aspect B1 is a method for ruling out sepsis or septic shock in a patient, the method comprising: calculating a neutrophil to lymphocyte ratio (NLR) of a blood sample from the patient; characterizing a white blood cell count (WBC) of the blood sample; calculating a monocyte population parameter of the blood sample; comparing the NLR to a first predetermined threshold, the WBC to a predetermined threshold range, and the monocyte population parameter to a second predetermined threshold; and determining whether the patient is not at risk for sepsis or septic shock.
[0171] Aspect B2 is the method of Aspect B1, wherein determining whether the patient is not at risk for sepsis or septic shock comprises: determining that the NLR is less than a first predetermined threshold; and the WBC is within a predetermined threshold range, or a monocyte population parameter is less than a second predetermined threshold, or both.
[0172] Aspect B3 is the method of Aspect B1 or B2, wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining that the NLR is less than a first predetermined threshold, the WBC is within a predetermined threshold range, and the monocyte population parameter is less than a second predetermined threshold.
[0173] Aspect B4 is the method of any of aspects B1 to B3, wherein the monocyte population parameter reflects monocyte activation.
[0174] Aspect B5 is the method of any one of Aspects B1 to B4, wherein the monocyte population parameter comprises monocyte distribution width (MDW).
[0175] Aspect B6 is the method of Aspect B5, wherein the second predetermined threshold is 19, 20, 21, 22, 23 or 24, and wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining that the MDW is less than the second predetermined threshold.
[0176] Aspect B7 is the method of Aspect B6, wherein the second predetermined threshold is 20, and wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining that the MDW is less than 20.
[0177] Aspect B8 is the method of any one of aspects B1 to B7, wherein the lower limit of the threshold range of WBC is 3.4×10 9 Cells / L, 4×10 9 cells / L, 4.5×10 9 cells / L or 5×10 9 cells / L; and the upper limit of the threshold range is 9.6×10 9 cells / L, 10×10 9 Cells / L, 11×10 9 cells / L or 12×10 9cells / L, and wherein determining whether the patient is not at risk for sepsis or septic shock includes determining that the WBC is within a threshold range.
[0178] Aspect B9 is the method of aspect B8, wherein the threshold range of WBC is 4×10 9 Cells / L to 12×10 9 cells / L, and wherein determining whether the patient is not at risk for sepsis or septic shock includes determining that WBC is greater than 4×10 9 cells / L and less than 12×10 9 Cells / L.
[0179] Aspect B10 is the method of any one of Aspects B1 to B9, wherein the first predetermined threshold is 6, 7, 8, 9, 10, 11 or 12, and wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining that the NLR is less than the first predetermined threshold.
[0180] Aspect B11 is the method of Aspect B10, wherein the first predetermined threshold is 10, and wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining that the NLR is less than 10.
[0181] Aspect B12 is the method of any of Aspects B1 to B11, wherein the patient presents with non-specific discomfort.
[0182] Aspect B13 is the method according to any of Aspects B1 to B12, wherein the patient exhibits symptoms of a systemic inflammatory disorder.
[0183] Aspect B14 is the method of any of Aspects B1 to B13, wherein the patient presents to an emergency department.
[0184] Aspect B15 is the method according to any of aspects B1 to B14, wherein the method is an in vitro method.
[0185] Aspect B16 is the method of Aspect B1, wherein the method further comprises discretizing one or more of the NLR, WBC, and monocyte population parameters to provide discretized values of one or more of the NLR, WBC, and monocyte population parameters; analyzing the discretized values of one or more of the NLR, WBC, and monocyte population parameters using a decision rule set; defining weights of the point system based on an odds ratio; and generating index points that can be added to provide an index score.
[0186] Aspect C1 is a method comprising an automated method for screening for sepsis or septic shock in a patient, the method comprising: calculating a neutrophil to lymphocyte ratio (NLR) of a blood sample from the patient; characterizing a white blood cell count (WBC) of the blood sample; calculating a monocyte population parameter of the blood sample; and determining whether the patient has an increased risk of sepsis or septic shock using a data processing module, wherein the data processing module comprises a processor and a tangible, non-transitory computer-readable medium, and the computer-readable medium is programmed with a computer application that, when executed by the processor, causes the processor to: compare the NLR to a first predetermined threshold to provide a first comparison, compare the monocyte population parameter to a second predetermined threshold to provide a second comparison, compare the WBC to a third predetermined threshold and a fourth predetermined threshold to provide a third comparison, and determine the risk of sepsis or septic shock based on the first comparison, the second comparison, and the third comparison.
[0187] Aspect C2 is the method of aspect C1, wherein if the first comparison is above a first predetermined threshold, the second comparison is above a second predetermined threshold, and the third comparison is below a third predetermined threshold or above a fourth predetermined threshold, determining that the risk of sepsis or septic shock indicates a suspicion of sepsis or septic shock.
[0188] Aspect C3 is the method of aspect C1 or C2, wherein the first predetermined threshold is 6, 7, 8, 9, 10, 11 or 12.
[0189] Aspect C4 is the method of aspect C3, wherein the first predetermined threshold is ten.
[0190] Aspect C5 is the method of any of Aspects C1 to C4, wherein the monocyte population parameter comprises the standard deviation of the monocyte volume.
[0191] Aspect C6 is the method of Aspect C5, wherein the standard deviation of the monocyte volume comprises a monocyte distribution width (MDW), and wherein the second predetermined threshold is 19, 20, 21, 22, 23 or 24.
[0192] Aspect C7 is the method of Aspect C6, wherein the standard deviation of the monocyte volume comprises a monocyte distribution width (MDW), and wherein the second predetermined threshold is 20.
[0193] Aspect C8 is the method of any one of Aspects C1 to C5, wherein the third predetermined threshold is 3.4×10 9 Cells / L, 4×10 9 cells / L, 4.5×10 9 cells / L or 5×10 9 cells / L; and the fourth predetermined threshold is 9.6×10 9cells / L, 10×10 9 Cells / L, 11×10 9 cells / L or 12×10 9 Cells / L.
[0194] Aspect C9 is the method of aspect C8, wherein the third predetermined threshold is 12×10 9 cells / L, and the fourth predetermined threshold is 4×10 9 Cells / L.
[0195] Aspect C10 is the method of any of aspects C1 to C9, further comprising altering the test reporting process based on the assessment of sepsis status.
[0196] Aspect C11 is the method of any one of aspects C1 to C10, further comprising: if the sepsis state is indicative of sepsis, treating the individual from whom the blood sample was obtained.
[0197] Aspect C12 is the method of any one of Aspects C1 to C11, further comprising: delivering a fluidically focused blood sample flow toward a cell interrogation zone of an optical element; and measuring the current (DC) impedance of blood sample cells passing through the cell interrogation zone individually with an electrode assembly; wherein the module determines the standard deviation of the monocyte volume based on the DC impedance measurement results of the blood sample cells.
[0198] Aspect D1 is the method of any one of Aspects A1 to A17, wherein determining whether the patient has an increased risk of sepsis or septic shock comprises generating output data by processing input data using a trained machine learning algorithm, wherein the input data comprises NLR from a blood sample of the patient, WBC from a blood sample of the patient, and a monocyte population parameter from a blood sample of the patient, and wherein the output data comprises information indicating whether the patient has an increased risk of sepsis or septic shock.
[0199] Aspect D2 is the method of any one of Aspects B1 to B14, wherein determining whether the patient has an increased risk of sepsis or septic shock comprises generating output data by processing input data using a trained machine learning algorithm, wherein the input data comprises NLR from a blood sample of the patient, WBC from a blood sample of the patient, and a monocyte population parameter from a blood sample of the patient, and wherein the output data comprises information indicating whether the patient is not at risk of sepsis or septic shock.
[0200] Aspect D3 is the method of Aspect D1 or Aspect D2, wherein the output data comprises a numerical value specifying the risk of sepsis or septic shock.
[0201] Aspect D4 is the method of aspect D3, wherein the output data further comprises a rationale for assigning a numerical value to the risk of sepsis or septic shock.
[0202] Aspect D5 is the method of any one of Aspects D1 to D4, wherein the method further comprises discretizing one or more of the NLR, WBC, and monocyte population parameters to provide discretized values of one or more of the NLR, WBC, and monocyte population parameters; analyzing the discretized values of one or more of the NLR, WBC, and monocyte population parameters with a decision rule set; defining weights for the point system based on an odds ratio; and generating index points that can be added to provide a numerical value for a specified risk of sepsis or septic shock.
[0203] Aspect E1 is a computer-implemented method comprising: obtaining, with a computing device, object value data of a patient, the object value data comprising a neutrophil-to-lymphocyte ratio (NLR) from a blood sample of the patient, a white blood cell count (WBC) from a blood sample of the patient, and a monocyte population parameter from a blood sample of the patient; and determining, with the computing device, whether the patient has an increased risk of sepsis or septic shock by using the object value data of the patient.
[0204] Aspect E2 is a method according to Aspect E1, wherein determining whether the patient has an increased risk of sepsis is performed by using at least one machine learning algorithm.
[0205] Aspect E3 is a method according to aspect E2, wherein determining whether the patient has an increased risk of sepsis comprises processing the patient's object-valued data by using a machine learning algorithm.
[0206] Aspect E4 is a computer-implemented method comprising: obtaining, using a computing device, object value data of a patient, the object value data comprising a neutrophil to lymphocyte ratio (NLR) from a blood sample of the patient, a white blood cell count (WBC) from a blood sample of the patient, and a monocyte population parameter from a blood sample of the patient; and determining, using the computing device, whether the patient is not at risk for sepsis or septic shock.
[0207] Aspect E5 is a method according to Aspect E4, wherein determining whether the patient is not at risk of sepsis or septic shock is performed by using at least one machine learning algorithm.
[0208] Aspect E6 is a method according to aspect E5, wherein determining whether the patient is not at risk of sepsis or septic shock comprises processing the patient's object-valued data by using a machine learning algorithm.
[0209] Aspect E7 is a method according to any one of Aspect E2, Aspect E3, Aspect E5 and Aspect E6, wherein a machine learning algorithm is trained by using a reference data set indicating reference object values associated with one or more reference patients; wherein the reference data set includes a plurality of reference object value data, each of the plurality of reference object value data including at least one of: a neutrophil to lymphocyte ratio (NLR) of a blood sample from a corresponding reference object; a white blood cell count (WBC) of a blood sample from a corresponding reference object; and a monocyte population parameter of a blood sample from a corresponding reference object.
[0210] Aspect E8 is a method according to any one of Aspects E1 to E7, wherein obtaining the patient's object value data comprises: calculating the NLR of a blood sample from the patient, characterizing the WBC of a blood sample from the patient, and / or calculating a monocyte population parameter of a blood sample from the patient.
[0211] Aspect E9 is the method of any one of Aspects E1 to E8, wherein the method further comprises: discretizing one or more of the NLR, WBC, and monocyte population parameters to provide discretized values of one or more of the NLR, WBC, and monocyte population parameters; analyzing the discretized values of one or more of the NLR, WBC, and monocyte population parameters using a decision rule set; defining weights for the point system based on odds ratios; and generating index points that can be added to provide object value data for the patient.
[0212] The present invention is illustrated by values for one or more of NLR, WBC and monocyte population parameters.Specific examples, substances, amounts and processes are to be broadly interpreted in accordance with the scope and spirit of the invention as set forth herein.
[0213] Example
[0214] Example 1
[0215] This example shows that a CBC differential panel including MDW, white blood cell count (WBC), and neutrophil to lymphocyte ratio (NLR) exhibits strong performance characteristics across a broad ED population, suggesting its utility as a rapid screen for sepsis and septic shock.
[0216] This example describes a study evaluating the performance of monocyte distribution width (MDW) alone and in combination with other routine CBC parameters as a screen for sepsis and septic shock in ED patients. A prospective cohort analysis was performed of adult patients who had a CBC obtained in an urban ED from January 2020 to July 2021. The performance of MDW, white blood cell count (WBC), and neutrophil-to-lymphocyte ratio (NLR) for the detection of sepsis and septic shock (Sepsis-3 criteria) was evaluated using diagnostic performance metrics.
[0217] 7952 ED patients were included in the cohort, of whom 180 met sepsis criteria; 43 had septic shock, and 137 without shock. Patients with septic shock had the highest MDW (median 24.8 U, IQR 22.0 to 28.1), and there was a decreasing trend in septic patients without shock (23.9 U, IQR 20.2 to 26.8), infected patients (20.4 U, IQR 18.2 to 23.3), and then controls (18.6 U, IQR 17.1 to 20.4). Individually, the AUCs for MDW to detect sepsis and septic shock were 0.80 (95% CI 0.77 to 0.84) and 0.85 (95% CI 0.80 to 0.91), respectively. The best performance was achieved when combined with WBC and NLR for the detection of sepsis (AUC 0.86, 95% CI 0.83 to 0.89) and septic shock (0.86, 95% CI 0.80 to 0.92).
[0218] Materials and methods
[0219] Study design and setting. This prospective cohort study was conducted in the ED of Johns Hopkins Hospital in Baltimore, Maryland, from January 21, 2020, to July 14, 2021. The study was approved by the Institutional Review Board (IRB) and followed the Standards for Reporting Studies of Diagnostic Accuracy (STARD) guidelines.
[0220] Selection of Participants. All adult patients (18 years and older) who had a CBC collected within 6 hours of arrival at the ED as part of routine clinical care were eligible for this study. Patients were continuously enrolled during the period when a member of the research team was present. Patients with missing valid MDW (e.g., small sample volume or poor sample quality), patients with MDW sample analysis more than 2 hours after blood collection, and patients with missing other CBC parameters (WBC, neutrophils, lymphocytes) within 6 hours of arrival were excluded. Repeat visits to the ED by the same patient during the study period were also excluded.
[0221] Measurements. Demographic, clinical (presenting complaint, comorbidities, vital signs, laboratories), and hospital utilization data were collected from electronic health record (EHR) systems. The chief complaint was entered from a list of options at the time of ED triage, and comorbidities were mined by grouping the diagnostic code (ICD-10) for the active problem available in the EHR at the time of the patient's visit. (World Health Organization. Classification of Diseases (ICD), available online: www.who.int / standards / classifications / classification-of-diseases (last accessed May 26, 2021); Levin et al. Ann Emerg Med. 2018;71(5):565-574.e2; Agency for Healthcare Quality Research. AHRQ QIICD-10-CM / PCS Specifications Version 7 Patient Safety Indicators Appendix, available online: www.qualityindicators.ahrq.gov / Downloads / Modules / PSI / V70 / TechSpecs / PSI_Appendix_I.pdf las (last accessed May 26, 2021)). The quick sequential organ failure assessment (qSOFA) score (range, 0 to 3 points) was estimated at triage using the first measurement of systolic blood pressure (<100 mm Hg = 1 point), respiratory rate (>22 breaths / min = 1 point), and altered mental status (1 point), indicated by a complaint related to altered mental status (Levin et al. Ann Emerg Med. 2018; 71(5):565-574.e2) or a Glasgow Coma Scale (GCS) <15 reported within 6 hours of ED arrival. (Seymour et al. JAMA 2016; 315(8):762). Mortality was defined as in-hospital death or discharge to hospice. Direct admission to the intensive care unit (ICU), hospitalization, and length of stay (from ED visit to actual discharge) were also reported.
[0222] MDW was analyzed in K2 EDTA tubes on a UniCel DxH900 analyzer (Beckman Coulter, Inc.) with software version 1.0. Critical values greater than 20 units were defined as abnormal. (Sprung et al. Intensive Care Med. 2006; 32(3):421-427; Bone et al. Chest. 1992; 101(6):1644-1655; Singer et al. JAMA. 2016; 315(8):801-810). MDW measurements were performed by research team members who were blinded to the patients' clinical information. MDW was not reported in the EHR; clinicians were blinded to MDW values when providing care for enrolled patients. Other CBC parameters (WBC and NLR) were measured on a separate hematology analyzer used in routine clinical practice and were available to the treating clinician. Abnormal WBC was defined as less than 4×10 9 Cells / L or greater than 12×10 9 cells / L (Bone et al. Chest. 1992; 101(6): 1644-1655; Levy et al. Intensive Care Medicine. 2003; 29(4): 530-538), and abnormal NLR was defined as greater than 10. (Farkas J Thorac Dis. 2020; 12(Suppl 1): S16-S21). Lactate (abnormal defined as greater than 2.0 mmol / L) (Singer et al. JAMA. 2016; 315(8): 801-810) and C-reactive protein (CRP) (abnormal defined as greater than 10 mg / L) (Laboratory Test Reference Ranges. Available online at www.abim.org / Media / bfijryql / laboratory-reference380ranges.pdf) were both measured at the request of the treating team and included in the analysis as controls if measured within 6 hours of ED visit. The immunosuppressed patient subgroup was defined as patients with neutropenia (absolute neutrophil count less than or equal to 1.5 × 10 9 cells / L) or patients with active problems that meet criteria for an immunocompromised state. (Agency for Healthcare Quality Research. Patient Safety Indicators Appendix to AHRQQIICD-10-CM / PCS Specifications, 7th Edition, available online at: www.qualityindicators.ahrq.gov / Downloads / Modules / PSI / V70 / TechSpecs / PSI_Appendix_1.372pdf (last accessed May 26, 2021)).
[0223] Results. The primary outcome was the presentation of sepsis with or without shock within 12 hours of CBC collection. For analysis, patients were assigned to four mutually exclusive groups based on previously validated criteria: control, infection, sepsis (without shock), or septic shock. (Singer et al. JAMA. 2016; 315(8): 801-810; Liu et al. J Biomed Inform. 2021; 121: 103879). Patients met infection criteria if they: (a) started a new antibiotic for at least 4 days (from the first day of administration to the last day) and were ordered to have a blood culture within 48 hours of arrival at the ED, or (b) met the ICD-10 code for infection diagnosis. (Liu et al. J Biomed Inform. 2021; 121: 103879). Patients who were on a shorter course of antibiotics were eligible if death occurred within 4 days of the start of treatment. The sepsis-3 definition using the Sequential Organ Failure Assessment (SOFA) (Singer et al. JAMA. 2016; 315(8):801-810) was used as the reference standard to define the sepsis groups (sepsis without shock and septic shock). Patients were assigned to the sepsis group if they met infection criteria and met at least one of the following SOFA criteria within 12 hours of CBC collection: (a) initiation of vasopressors, (b) initiation of mechanical ventilation, (c) doubling of serum creatinine level, (d) estimated glomerular filtration rate decreased by 50% from baseline, (e) bilirubin level greater than 2.0 mg / dL and doubled from baseline, (f) platelet count less than 100×10 9 / L and the decrease is greater than 50% from the baseline (the baseline must be greater than 100×10 9 Patients who met the criteria for sepsis and were started on vasopressors and had a lactate value greater than 2 mmol / L were assigned to the septic shock group. Patients who did not meet the criteria for infection or sepsis were included in the control group.
[0224] Patient outcome classification was assigned by an automated algorithm applied to EHR data. Two physicians from the study team performed a non-blinded chart review of a subset of 100 patients with sepsis (including septic shock) and 100 non-sepsis patients (infection or control). (Liu et al. J Biomed Inform. 2021;121:103879). The review was conducted to assess the reliability and accuracy of the algorithm with respect to the above definitions. The result of the review was a reliable classification of sepsis confirmed with a positive predictive value (PPV) of 99% and a negative predictive value (NPV) of 100%.
[0225] Analysis. Continuous variables were expressed as medians with interquartile ranges (IQRs) and compared using the Mann-Whitney U test. Categorical variables were expressed as numbers and percentages and compared using the χ2 test. Correlation coefficients were calculated using the Spearman rank method. Diagnostic performance was assessed using a binary classification approach. The area under the receiver operating characteristic curve (AUC) was calculated using a logistic regression model with sepsis (sepsis without shock or septic shock) and septic shock as separate response variables. Leukocyte parameters were modeled as continuous variables individually (single predictor) and in combination (multiple predictors). Comparison of AUCs and their CIs was assessed using the De Long method. (DeLong et al. Biometrics 1988;44(3):837-845). Sensitivity, specificity, positive and negative predictive values, and likelihood ratios were calculated using laboratory cutoff values and defined as dichotomized as normal or abnormal. Patients with missing lactate or CRP were excluded from the corresponding subgroup analyses. No imputation or interpolation methods were applied to any clinical data used to derive sepsis outcomes. All analyses were performed in Python version 3.
[0226] Table 1: Characteristics of study patients
[0227] total Comparison Infect Sepsis Septic shock Patient No. 7952 6597 1175 137 43 Gender Female NO.(%) 4196(52.8%) 3494(53.0%) 621(52.9%) 54(39.4%) 27(62.8%) Age, median (IQR) [years] 50.0(34.0-63.0) 49.0(33.0-62.0) 53.0(36.0-65.0) 62.0(49.0-69.0) 66.0(53.5-73.5) Race, No.(%) Black people 4567(57.4%) 3843(58.3%) 635(54.0%) 64(46.7%) 25(58.1%) White 2499(31.4%) 1999(30.3%) 423(36.0%) 60(43.8%) 17(39.5%) other 886(11.1%) 755(11.4%) 117(10.0%) 13(9.5%) 1(2.3%) Chief complaint, No.(%) stomach ache 802(10.1%) 653(9.9%) 136(11.6%) 10(7.3%) 3(7.0%) Altered mental status 130(1.6%) 100(1.5%) 19(1.6%) 7(5.1%) 4(9.3%) Chest pain 749(9.4%) 698(10.6%) 50(4.3%) 1(0.7%) 0(0.0%) Dizziness 166(2.1%) 150(2.3%) 14(1.2%) 0(0.0%) 2(4.7%) fever 162(2.0%) 89(1.3%) 57(4.9%) 13(9.5%) 3(7.0%) General weakness 97(1.2%) 72(1.1%) 17(1.4%) 6(4.4%) 2(4.7%) Low blood pressure 46(0.6%) 15(0.2%) 24(2.0%) 4(2.9%) 3(7.0%) Shortness of breath 632(7.9%) 489(7.4%) 118(10.0%) 20(14.6%) 5(11.6%) Comorbidities, NO.(%) Coronary artery disease 614.0(7.7%) 486.0(7.4%) 110.0(9.4%) 17.0(12.4%) 1.0(2.3%) cancer 1157.0(14.5%) 889.0(13.5%) 216.0(18.4%) 38.0(27.7%) 14.0(32.6%) Cerebrovascular disease 389.0(49%) 315.0(4.8%) 60.0(5.1%) 11.0(8.0%) 3.0(7.0%) diabetes 1057.0(13.3%) 819.0(12.4%) 200.0(17.0%) 31.0(22.6%) 7.0(16.3%) Heart failure 475.0(6.0%) 368.0(5.6%) 82.0(7.0%) 18.0(13.1%) 7.0(16.3%)
[0228] total Comparison Infect Sepsis Septic shock hypertension 2030.0(25.5%) 1611.0(24.4%) 358.0(30.5%) 47.0(34.3%) 14.0(32.6%) Immunocompromise 850.0(10.7%) 614.0(9.3%) 189.0(16.1%) 38.0(27.7%) 9.0(20.9%) Kidney disease 831.0(10.5%) 593.0(9.0%) 204.0(17.4%) 26.0(19.0%) 8.0(18.6%) Liver disease 897.0(113%) 719.0(10.9%) 154.0(13.1%) 18.0(13.1%) 6.0(14.0%) Previous respiratory failure 43.0(0.5%) 30.0(0.5%) 11.0(0.9%) 2.0(1.5%) 0.0(0.0%) qSOFA ≥ 2, No.% 94(1.2%) 54(0.8%) 19(1.6%) 11(8.0%) 10(23.3%) Secondary Outcomes Mortality rate, No.(%) 132(1.7%) 67(1.0%) 37(3.1%) 19(13.9%) 9(20.9%) Intensive care, No. (%) 239(3.0%) 121(1.8%) 53(4.5%) 36(26.3%) 29(67.4%) Hospitalization, No.(%) 2717(34.2%) 1864(28.3%) 673(57.3%) 137(100.0%) 43(100.0%) Length of hospital stay, median (IQR) [hours] 18.3(8.1-80.3) 14.6(7.6-56.8) 72.9(13.5-167.5) 219.4(149.0-392.3) 273.6(156.3-387.9) Laboratory results, median (IQR) [unit] Monocyte distribution width [U] 18.8(17.3-21.0) 18.6(17.1-20.4) 20.4(18.2-23.3) 23.9(20.2-26.8) 24.8(22.0-28.1) White blood cells, count [G / L] 7.4(5.6-9.8) 7.1(5.6-9.3) 8.7(6.2-11.7) 13.0(8.9-18.6) 14.8(8.7-17.8) Neutrophil to lymphocyte ratio 3.0(1.9-5.4) 2.8(1.8-4.7) 4.4(2.4-8.5) 11.2(6.6-19.6) 9.6(5.4-18.8)
[0229] Abbreviations: qSOFA: quick sequential organ failure assessment, No: number, IQR: interquartile range, U: unit
[0230] Table 2: Diagnostic performance of monocyte distribution width, white blood cell count, and neutrophil to lymphocyte ratio alone and in combination for sepsis (with or without shock) and septic shock
[0231]
[0232] Abbreviations: qSOFA: rapid sequential organ failure assessment, MDW: monocyte distribution width, WBC: white blood cell count, NLR: neutrophil-to-lymphocyte ratio, U: unit, AUC: area under the curve, PPV: positive predictive value, NPP: negative predictive value, LR+: positive likelihood ratio, LR-: negative likelihood ratio, CI: confidence interval
[0233] result
[0234] Characteristics of the study subjects. A total of 8,915 patients whose MDW was measured within 6 hours of ED arrival were included in the study. Figure 1As shown in Figure 100 of , patients were excluded due to a delay of greater than 2 hours from blood collection to MDW analysis (570 patients), invalid MDW measurement results (171), and missing relevant WBC, neutrophil, or lymphocyte counts (222). This left a final cohort of 7,952 patients, including 6,597 (83.0%) controls, 1,175 (14.8%) patients with infection, 137 (1.7%) who met sepsis criteria without shock, and 43 (0.5%) who met criteria for septic shock. As shown in Table 1, patients who met criteria for infectious disease outcomes tended to be older and more likely to have comorbidities such as cancer, heart failure, and renal disease. They were also more likely to meet 2 or more qSOFA criteria at presentation, require hospitalization or ICU admission, and experience death.
[0235] Main Results. Distribution of MDW, WBC and NLR Figure 2 As shown in Figure 2 As seen in the results of the MDW analysis, patients with septic shock had the highest MDW (median: 24.8 U, IQR 22.0 to 28.1), and a decreasing trend in MDW was observed in patients with sepsis (23.9 U, IQR 20.2 to 26.8) and infection (20.4 U, IQR 18.2 to 23.3), while the lowest value was observed in control patients (18.6 U, IQR 17.1 to 20.4). WBC and NLR could distinguish between sepsis and non-sepsis groups (control and infection), but showed lower discrimination between sepsis (no shock) and septic shock groups compared with MDW (P = 0.048). In addition, MDW showed low positive correlation with WBC (rho=0.09, 95% CI [0.07 to 0.11]) and NLR (rho=0.19, 95% CI [0.17 to 0.22]), while WBC was moderately correlated with NLR (rho=0.52, 95% CI [0.50 to 0.53]).
[0236] The diagnostic performance of qSOFA and white blood cell parameters (MDW, WBC, NLR) for the sepsis group is shown in Table 2. MDW detected sepsis with an AUC of 0.80 (95% CI 0.77 to 0.84), and detected septic shock with an AUC of 0.85 (95% CI 0.79 to 0.91). In contrast, for sepsis and septic shock, the AUCs for WBC were 0.77 (95% CI 0.73 to 0.81) and 0.79 (95% CI 0.71 to 0.87), respectively, and the AUCs for NLR were 0.84 (95% CI 0.81 to 0.87) and 0.81 (95% CI 0.73 to 0.88), respectively. Using a MDW cutoff of 20 U or greater as a test for sepsis showed a sensitivity of 77.8% (95% CI 71.1 to 83.9) and a specificity of 66.8% (95% CI 65.8 to 67.9%). For sepsis, the overall diagnostic performance (AUC) of MDW and NLR alone was superior to qSOFA (P<0.05). As seen in Table 2, the combined use of MDW, WBC, and NLR improved the overall diagnostic performance for sepsis to AUC of 0.86 (95% CI 0.83 to 0.89) and for septic shock to AUC of 0.86 (95% CI 0.80 to 0.92).
[0237] Subgroup Analyses. During routine care in the ED, lactate measurements were performed in a subgroup of 2,712 patients (34.1% of the total cohort), and CRP measurements were performed in a subgroup of 542 patients (6.8%). Figure 3A shows the distribution of lactate, and Figure 3B The distribution of CRP is shown, compared with the leukocyte parameters (MDW, WBC, NLR) of these corresponding subgroups. Figure 3A As seen in the 2016 study, lactate demonstrated reliable differences between sepsis and non-sepsis (control and infection) groups, with limited differences between sepsis (no shock) and septic shock groups. CRP in a smaller sample showed a similar trend, with no significant differences between sepsis (no shock) and septic shock groups ( Figure 3B In both subgroups where additional laboratory tests were performed, MDW maintained an increasing trend between the control, infection, sepsis, and septic shock groups. Figure 4 This trend was also maintained in the group of 965 patients (12.2%) who met the immunosuppression criteria as seen in the previous study.
[0238] discuss
[0239] Despite widespread recognition that early initiation of targeted therapies for sepsis is critical to improved outcomes, rapidly identifying patients with the condition remains a major challenge. (Morr et al. BMC Emerg Med. 2017;17(1):11). The diagnosis of sepsis is complicated by ambiguous presentations and the lack of biomarkers or other ancillary tests that reliably confirm or exclude the disease. (Al Jalbout et al. The Journal of Applied Laboratory Medicine. 2019;3(4):724-729; Pierrakos et al. Crit Care. 2020;24(l):287; Boushra et al. J Emerg Med. 2019;56(l):36-45). Sepsis screening is particularly challenging in the ED, where systemic inflammatory response syndrome (SIRS) and organ failure are often caused by noninfectious pathologies, and patients with occult infection may present before developing telltale signs of sepsis (e.g., tachycardia, hypotension, altered mental status) as detected by tools such as qSOFA that have been applied for screening (Singer et al. JAMA. 2016; 315(8):801-810; Serafim et al. Chest. 2018; 153(3):646-655; Anand et al. Chest. 2019; 156(2):289-297).
[0240] This example demonstrates that MDW can be used for both ED-based sepsis screening and disease severity stratification. Taken alone, MDW was the most sensitive marker tested for both sepsis and septic shock, outperforming qSOFA, WBC, and NLR (Table 2). It also demonstrated an NPV of 99.2% for sepsis and 99.9% for septic shock. These results suggest that MDW is a strong candidate for broad-based screening aimed at identifying unsuspected cases of sepsis. In addition, MDW is unique in differentiating the severity of disease (e.g., septic shock and sepsis) compared to WBC, NLR, lactate, and CRP. For example, the NLR (AUC = 0.84), which reported the highest discriminatory power for sepsis in this cohort, showed limited ability to distinguish sepsis without shock from septic shock; this is consistent with previous findings in high-risk populations (e.g., ICU). (Farkas, J Thorac Dis. 2020; 12(Suppl 1): S16-S21). Thus, the complementary clinical properties of different leukocyte parameters (e.g., utility for screening versus risk stratification) suggest that they are most useful when used in combination.
[0241] When applied together, MDW, WBC, and NLR achieved an AUC of 0.86 for sepsis and septic shock (Table 2); a sensitivity of 92.2% for sepsis and 97.7% for septic shock. These sensitivities translate into negative likelihood ratios of 0.14 and 0.04, respectively. For patients presenting to the ED with a low pretest probability (e.g., 20%), sepsis and septic shock will be effectively ruled out (post-test probabilities of 3% and 1%, respectively) by not meeting the threshold criteria for any of these three parameters. In addition, it is likely that additional accuracy will be achieved by incorporating algorithms with other clinical data, such as patient demographics, medical history, chief complaints, and vital signs; all of which may be available before CBC results are available. (Levin et al. Ann Enter g Med. 2018; 71(5):565-574.e2).
[0242] The usefulness of MDW, WBC, and NLR as part of a CBC differential should not be underestimated. Other markers of sepsis (e.g., lactate, CRP, and procalcitonin) are commonly used for risk stratification of sepsis, but none demonstrates optimal diagnostic performance when used alone, and they are not consistently clinically available in all EDs. In contrast, identification of disease-specific patterns within a routinely used laboratory panel allows for identification of a clinically time-sensitive condition (sepsis) when the disease is not suspected and has potential value in guiding interventions for those patients who are most at risk for a missed or delayed diagnosis and adverse outcome. In the present study, MDW was comparable to lactate and CRP in a highly selected group of patients for whom treating clinicians ordered these tests ( Figure 3 ), whereas MDW was available for the entire study cohort. WBC, NLR, and MDW individually demonstrated predictive value and unique diagnostic performance characteristics ( Figure 2 and Table 2). However, the lack of correlation between MDW and other CBC parameters indicates that MDW has an important additional role (Crouser et al. Chest. 2017; 152(3):518-526) and can help optimize the use of CBC results (Farkas, J Thorac Dis. 2020; 12(Suppl 1):S16-S21).
[0243] This example describes the largest clinically focused MDW study to date. These findings support the findings of several smaller studies, which showed that MDW alone has fairly good accuracy for detecting sepsis in an undifferentiated ED population. (Crouser et al. Crit Care Med. 2019; 47(8): 1018-1025; Crouser et al. Chest. 2017; 152(3): 518-526; Crouser et al. J Intensive Care. 2020; 8: 33; Agnello et al. Int J Lab Hematol. 2021; 23(4): O183; Pollilli et al. PLoS ONE. 2020; 15(l): e0227300; Le et al. Critical Care Medicine. 2020; 48(l): 12). This study extends these findings by evaluating the performance of MDW alone and in combination with multiple routinely reported CBC components to optimize sensitivity and specificity. This example also describes the performance of MDW relative to both lactate and CRP and evaluates its performance in a subset of immunosuppressed patients. Although this subanalysis was limited by its small sample size, MDW was effective in distinguishing patients with infection and sepsis from those without infection, and a similar trend in the MDW signal observed in this sample to that in the larger population was observed ( Figure 4 ). These data strengthen the evidence supporting the use of MDW for broad-based sepsis screening and advocate its inclusion in comprehensive algorithms for sepsis diagnosis and illness severity estimation. (Le et al. Critical Care Medicine. 2020;48(l):12).
[0244] The complete disclosures of all patents, patent applications and publications cited herein and electronically available materials are incorporated by reference. If there is any inconsistency between the disclosure of the present application and the disclosure of any document incorporated herein by reference, the disclosure of the present application shall prevail. The foregoing detailed description and examples are given only for clear understanding. No unnecessary limitations should be understood therefrom. The present invention is not limited to the exact details shown and described, and obvious variations to those skilled in the art will be included in the present invention defined by the claims.
Claims
1. A method for screening for sepsis or septic shock in a patient, the method comprising: calculating a neutrophil to lymphocyte ratio (NLR) from a blood sample from the patient; Characterize the white blood cell count (WBC) of a blood sample; calculating a monocyte population parameter of the blood sample; comparing the NLR to a first predetermined threshold, the WBC to a predetermined threshold range, and the monocyte population parameter to a second predetermined threshold; as well as Determining whether the patient is at increased risk for sepsis or septic shock.
2. The method of claim 1, wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining: NLR is greater than the first predetermined threshold, WBC is outside the predetermined threshold range, or The monocyte population parameter is greater than the second predetermined threshold, or a combination thereof.
3. The method of claim 1 or 2, wherein determining whether the patient has an increased risk of sepsis or septic shock comprises determining: NLR is greater than the first predetermined threshold, WBC is outside the predetermined threshold range, and The monocyte population parameter is greater than the second predetermined threshold.
4. The method according to any one of claims 1 to 3, wherein the monocyte population parameter reflects monocyte activation.
5. The method according to any one of claims 1 to 4, wherein the monocyte population parameter comprises monocyte distribution width (MDW).
6. The method according to claim 5, wherein the second predetermined threshold is 20, and wherein, Determining whether the patient has an increased risk for sepsis or septic shock includes determining that the MDW is greater than 20.
7. The method according to any one of claims 1 to 6, wherein the threshold range is 4×10 9 Cells / L to 12×10 9 cells / L, and among them, Determining whether the patient is at increased risk for sepsis or septic shock includes determining a WBC count of less than 4 × 10 9 Cells / L or greater than 12×10 9 Cells / L.
8. The method according to any one of claims 1 to 7, wherein the first predetermined threshold is 10, wherein, Determining whether the patient has an increased risk for sepsis or septic shock includes determining that the NLR is greater than 10.
9. The method according to any one of claims 1 to 8, wherein the patient exhibits non-specific discomfort.
10. The method according to any one of claims 1 to 9, wherein the patient exhibits symptoms of a systemic inflammatory disorder.
11. The method according to any one of claims 1 to 10, wherein the patient presents to an emergency department.
12. The method according to any one of claims 1 to 11, wherein the method is an in vitro method.
13. The method of any one of claims 1 to 12, wherein the method further comprises administering a treatment for sepsis.
14. The method of claim 13, wherein administering a treatment for sepsis comprises administering an antibiotic preparation, an intravenous fluid, a vasopressor, a corticosteroid, insulin, an analgesic, a sedative, or an immune enhancing therapy, or a combination thereof.
15. The method of claim 13 or 14, wherein the method further comprises determining the success of the treatment of sepsis.
16. The method according to any one of claims 1 to 15, wherein the method further comprises: discretizing one or more of NLR, WBC, and the monocyte population parameter to provide discretized values of one or more of NLR, WBC, and the monocyte population parameter, analyzing the discretized values of one or more of NLR, WBC, and the monocyte population using a decision rule set, Define the weights of the point system based on odds ratios, and Index points are generated for one or more of the NLR, WBC and monocyte population parameters which can be summed to provide an index score.
17. The method according to any one of claims 1 to 16, wherein the method further comprises: discretizing one or more of NLR, WBC, and the monocyte population parameter to provide one or more discretized values; analyzing the one or more discretized values using a set of decision rules; The weights of the point system were defined based on odds ratios; as well as Index points are generated which can be summed to provide an index score.
18. A method of ruling out sepsis or septic shock in a patient, the method comprising: calculating a neutrophil to lymphocyte ratio (NLR) from a blood sample from the patient; characterizing a white blood cell count (WBC) of the blood sample; calculating a monocyte population parameter of the blood sample; comparing the NLR to a first predetermined threshold, the WBC to a predetermined threshold range, and the monocyte population parameter to a second predetermined threshold; as well as A determination is made as to whether the patient is not at risk for sepsis or septic shock.
19. The method of claim 18, wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining: The NLR is less than a first predetermined threshold; and WBC is within a predetermined threshold range, or the monocyte population parameter is less than the second predetermined threshold, or both.
20. The method of claim 18 or 19, wherein determining whether the patient is not at risk for sepsis or septic shock comprises determining: NLR is less than a first predetermined threshold, WBC is within a predetermined threshold range, and The monocyte population parameter is less than a second predetermined threshold.
21. The method of any one of claims 18 to 20, wherein the monocyte population parameter reflects monocyte activation.
22. The method of any one of claims 18 to 21, wherein the monocyte population parameter comprises monocyte distribution width (MDW).
23. The method of claim 22, wherein the second predetermined threshold is 20, and wherein, Determining whether the patient is not at risk for sepsis or septic shock includes determining that the MDW is less than 20.
24. The method according to any one of claims 18 to 23, wherein the threshold range of WBC is 4×10 9 Cells / L to 12×10 9 cells / L, and among them, Determining whether the patient is not at risk for sepsis or septic shock includes determining that the WBC count is greater than 4 × 10 9 cells / L and less than 12×10 9 Cells / L.
25. The method according to any one of claims 18 to 24, wherein the first predetermined threshold is 10, and wherein, Determining whether the patient is not at risk for sepsis or septic shock includes determining that the NLR is less than 10.
26. The method according to any one of claims 18 to 25, wherein the patient exhibits non-specific discomfort.
27. The method of any one of claims 18 to 26, wherein the patient exhibits symptoms of a systemic inflammatory disorder.
28. The method of any one of claims 18 to 27, wherein the patient presents to an emergency department.
29. The method according to any one of claims 18 to 28, wherein the method is an in vitro method.
30. A method comprising an automated method for screening for sepsis or septic shock in a patient, the method comprising: calculating a neutrophil to lymphocyte ratio (NLR) from a blood sample from the patient; characterizing a white blood cell count (WBC) of the blood sample; calculating a monocyte population parameter of the blood sample; as well as determining whether the patient has an increased risk of sepsis or septic shock using a data processing module, wherein the data processing module includes a processor and a tangible, non-transitory computer-readable medium, and the computer-readable medium is programmed with a computer application that, when executed by the processor, causes the processor to: compare the NLR to a first predetermined threshold to provide a first comparison, compare the monocyte population parameter to a second predetermined threshold to provide a second comparison, compare the WBC to a third predetermined threshold and a fourth predetermined threshold to provide a third comparison, and determine the risk of sepsis or septic shock based on the first comparison, the second comparison, and the third comparison.
31. The method according to claim 30, wherein: The risk of sepsis or septic shock is determined if the following occur: the first comparison is above the first predetermined threshold, the second comparison is above the second predetermined threshold, and The third comparison is below the third predetermined threshold or above the fourth predetermined threshold.
32. The method according to claim 30 or 31, wherein the first predetermined threshold is 10.
33. The method of any one of claims 30 to 32, wherein the monocyte population parameter comprises the standard deviation of monocyte volume.
34. The method of claim 32, wherein the standard deviation of the monocyte volume comprises a monocyte distribution width (MDW), and wherein the second predetermined threshold is 20.
35. The method according to any one of claims 30 to 34, wherein the third predetermined threshold is 12×10 9 cells / L and the fourth predetermined threshold is 4×10 9 Cells / L.
36. The method according to any one of claims 30 to 35, further comprising: Change the test reporting process based on the assessment of sepsis status.
37. The method according to any one of claims 30 to 36, further comprising: If the sepsis status is indicative of sepsis, treating the individual from whom the blood sample was obtained.
38. The method according to any one of claims 34 to 37, further comprising: delivering the hydrodynamically focused stream of the blood sample toward a cell interrogation region of an optical element; as well as Measuring the current (DC) impedance of cells of the blood sample passing through the cell interrogation zone individually with an electrode assembly; as well as Wherein the module determines a standard deviation of the mononuclear cell volume based on a DC impedance measurement of cells of the blood sample.
Citation Information
Patent Citations
Ski grippers
US20170014708A1
Evolving rule based contact exchange
US20190028486A1
Indirect Authorization Transport
US20190028487A1
Automated inventory control system using pivotable divider
US20200041535A1
Nanoscale Dynamic Mechanical Analysis via Atomic Force Microscopy (AFM-nDMA)
US20200041541A1
Cited By
Biomarker for predicting prognosis condition of sepsis and application
CN120183699A
